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ABSTRACT: Transcription factors GATA4 and NKX2-5
directly interact and synergistically activate several cardiac
genes and stretch-induced cardiomyocyte hypertrophy.
Previously, we identiﬁed phenylisoxazole carboxamide 1 as a
hit compound, which inhibited the GATA4−NKX2-5 tran-
scriptional synergy. Here, the chemical space around the
molecular structure of 1 was explored by synthesizing and
characterizing 220 derivatives and structurally related
compounds. In addition to the synergistic transcriptional
activation, selected compounds were evaluated for their eﬀects
on transcriptional activities of GATA4 and NKX2-5
individually as well as potential cytotoxicity. The structure−
activity relationship (SAR) analysis revealed that the aromatic
isoxazole substituent in the southern part regulates the inhibition of GATA4−NKX2-5 transcriptional synergy. Moreover,
inhibition of GATA4 transcriptional activity correlated with the reduced cell viability. In summary, comprehensive SAR analysis
accompanied by data analysis successfully identiﬁed potent and selective inhibitors of GATA4−NKX2-5 transcriptional synergy
and revealed structural features important for it.
■ INTRODUCTION
Protein−protein interactions (PPIs) are critical regulatory
events in physiology and diseases, and they represent an
attractive target for pharmacological interventions.1 However,
targeting PPIs with small molecules is challenging due to the
large surface area involved in protein−protein binding and the
lack of clear binding pockets for small molecules at many
protein−protein interfaces. Nevertheless, the number of
successful examples of small molecule modulators of PPIs
has been growing,1,2 and Lawson et al. recently concluded that
small molecules provide signiﬁcant opportunities for allosteric
modulation of PPIs.3 Transcription factors are the fundamental
regulators of gene expression, and their PPIs are of pivotal
importance in the regulation of biological systems.4 The
GATA family of transcription factors consists of six proteins
(GATA1−6), which are involved in a variety of physiological
and pathological processes.5−7 GATA1−3 are required for
diﬀerentiation of mesoderm and ectoderm-derived tissues,
whereas GATA4−6 are implicated in the development and
diﬀerentiation of endoderm- and mesoderm-derived tissues
such as induction of diﬀerentiation of embryonic stem cells
and cardiovascular embryogenesis.6 In the developing heart,
GATA4 is one of the earliest-expressed transcription factors8
and is essential for normal cardiac development.9−12 In the
postnatal heart, GATA4 acts as a critical regulator of hormone
response and mechanical stress13−16 as well as cardiac repair
and regeneration.17−20
GATA4 actions involve combinatorial interactions with a
number of other nuclear proteins, reinforcing their activity and
tissue speciﬁcity.5−7 For example, functional cardiomyocytes
can be directly induced from ﬁbroblasts by a combination of
three cardiac transcription factors, GATA4, MEF2C, and
TBX5, in vitro and in vivo.21,22 Most of the PPIs occur through
the C-terminal zinc ﬁnger, which also mediates DNA binding
and is highly conserved throughout the GATA family.5
GATA4 regulates myocardial gene expression by interacting
with diﬀerent cardiac speciﬁc transcription factors, such as
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NKX2-5, NFAT, and MEF2.5−7 NKX2-5, a member of the
evolutionary conserved NK family of homeobox proteins, is a
critical GATA4 cofactor and essential for heart develop-
ment.23−25 GATA4 and NKX2-5 directly interact and
synergistically activate several genes including those encoding
atrial natriuretic peptide (ANP) and B-type natriuretic peptide
(BNP).7,26 Mutational studies have shown that the tandem
GATA consensus sites of the proximal promoter in
combination with an NKX2-5 binding element are important
for the stretch-activated BNP transcription.27 As the precise
balance of GATA4−NKX2-5 interaction is essential for
mechanical stretch-induced cardiomyocyte hypertrophy, the
functional modulation of their interaction could present a
novel approach for cardiac repair under pathophysiological
conditions.
We have previously shown that single point mutations can
interfere with GATA4 and NKX2-5 interaction,28 implicating
that this PPI is targetable by small molecules to achieve direct
inhibition, activation, or allosteric modulation. Recently, we
reported the identiﬁcation of several compounds that aﬀect the
transcriptional synergy of GATA4 and NKX2-5.29,30 In
addition, we have shown that a small molecule inhibitor of
GATA4−NKX2-5 transcriptional synergy reduces cardiomyo-
cyte hypertrophic response in vitro, ameliorates hypertrophic
signaling in vivo, and improves cardiac function in vivo in
experimental models of myocardial infarction and hyper-
tension.29,31,32 These studies led to the identiﬁcation of
compounds 1−3 (Figure 1), which either increase (2) or
inhibit (1 or 3) the transcriptional synergy of GATA4 and
NKX2-5.29 Our aim in this study was to optimize the original
isoxazole hit compound 1 by means of synthesis and biological
investigation of 220 structurally related compounds with
modiﬁed or alternative northern, central, and southern parts
(Figure 2). Additionally, this structure−activity relationship
(SAR) analysis was augmented by 29 commercial and 8
previously published compounds33 that were tested with a
luciferase reporter assay to examine their eﬀects on the
transcriptional synergy of GATA4 and NKX2-5. The most
potent compounds were also tested independently in luciferase
reporter assays for NKX2-5 and GATA4 activity. Furthermore,
toxicity of the selected compounds was studied with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) and lac-
tate dehydrogenase (LDH) assays in the COS-1 cell line.
■ RESULTS
Chemistry. Synthesis of Compounds. To gain information
on the chemical space of the hit compound 1 in regard to the
ability of such molecules to inhibit GATA4−NKX2-5 tran-
scriptional synergy, we synthesized 220 structurally related
compounds. For a simpliﬁed view, we divided the chemical
structure 1 into three sections, that is, northern, central, and
southern parts (Figure 2). The original central amide linker in
1 was replaced with other linkers, such as alkyl, amino, inverse
amide, imino, ether, and thioamide linkers. The alternative
southern parts comprise structural changes of the isoxazole
substituents (Ph or Me), scaﬀold hopping, as well as
exploration of other heterocycles as surrogates of the original
isoxazole ring. In the northern part, we mainly experimented
with substituted phenyl moieties in the para position. A few
compounds comprised of heterocycles in the northern part and
some compounds devoid of a central or northern part were
prepared.
Northern Part. The synthesis of selected derivatives with
alternative northern parts is shown in Scheme 1. The amides
4a−k were obtained from various amines 5a−k and 5-methyl-
3-phenylisoxazole-4-carboxylic acid 6 in the presence of
N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hex-
aﬂuorophosphate (HBTU), or in some cases O-(7-azabenzo-
triazol-1-yl)-N,N,N′,N′-tetramethyluronium hexaﬂuorophos-
phate (HATU) as a coupling agent and Hünig’s base
(DIPEA). The quaternary ammonium salt 7 was obtained by
alkylating compound 4i with iodomethane in methanol under
microwave irradiation. The nitro derivative 8 was obtained
from compound 5i with NOBF4 in acetonitrile. The reductive
treatment of compound 8 with zinc in an equimixture of acetic
acid and methanol produced the corresponding amine 9. The
esters 10a−d were then prepared from the methyl benzoate 11
by a base-assisted ester hydrolysis followed by alkylation of the
resulting benzoic acid derivative 12 with alkyl halides in the
presence of K2CO3 in N,N-dimethylformamide (DMF).
Figure 1. Representative examples of the previously reported
modulators of GATA4−NKX2-5 transcriptional synergy.29 Com-
pounds 1 and 3 inhibit and compound 2 enhances transcriptional
synergy of GATA4 and NKX2-5.
Figure 2. Synthesis strategy for structural modiﬁcations of compound 1.
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Compound 11 was prepared via acid chloride of 6, generated
with oxalyl chloride in the presence of catalytic amount of
DMF. 4-(tert-Butyl)thiazol-2-amine 5k was synthesized by
letting thiourea and 1-bromopinacolone 14 react in ethanol
under microwave irradiation at 120 °C.34 Compound 15 was
prepared from the corresponding ethynyl(trimethylsilyl)
derivative 4j in the presence of tert-butyl bromide and n-
tetrabutylammonium ﬂuoride (TBAF) in THF.
Central Part. The investigation of the central part was
important to evaluate the role of changes in hydrogen-bond
accepting or donating properties of the central linker, the
importance of its electrostatic eﬀects, and aspects of ﬂexibility
in this molecular region. The central part of the hit compound
1 (an amide linker) has both hydrogen-bond donating and
accepting properties. It can be considered as relatively polar
and due to the delocalized lone pair of nitrogen electrons as
quite rigid. Selected compounds are presented in Schemes 2
and 3. The acetamide derivative 16 was prepared from N,N-
diethyl-p-phenylenediamine 17 and 5-methyl-3-phenylisoxa-
zole-4-carbaldehyde 18 via the intermediate imine 19. The
imine 19 was subsequently reduced to the corresponding
amine 20 with sodium borohydride, followed by treatment
with acetyl chloride in pyridine. The sulfonamide 21 was
obtained from a reaction between 5-methyl-3-phenylisoxazole-
4-sulfonyl chloride 22 and diamine 17 in pyridine. Thioamide
23 was obtained by reacting 1 with Lawesson’s reagent and
could be derivatized by base treatment (Li2CO3 and NaH) and
a reaction with alkyl halides to give S-alkylated derivatives
24a,b. The alkylated amides 25a−c were obtained from 1 by
deprotonation with sodium hydride and subsequent alkylation,
and the thioamide analogue 26, in turn, was obtained from the
N-methylated amide 25a and Lawesson’s reagent.
The inverse amide 27 was prepared from 5-methyl-3-
phenylisoxazol-4-amine 28 and 4-(diethylamino)benzoic acid
29. Because of the poor reactivity of the electron-rich carboxyl
group of 29 (electron-donating eﬀects of its para substituent),
a reaction sequence via the acid chloride (generated with oxalyl
chloride and DMF, cat.) was given preference over the
generally applied HBTU-mediated coupling. The N,N-
disubstituted amines 30a−d were prepared through the initial
imine intermediate 31 of the reaction between 4-
(diethylamino)benzaldehyde 32 and isoxazolylamine 28. The
carbon−nitrogen double bond of the imine was reduced with
NaBH4 to give the corresponding secondary amine 33,
followed by a reaction with an appropriate reagent (alkyl
halides, anhydride, or isocyanate) under basic conditions.
Central Part: Ethers. The synthesis of the compounds 34a−
e, 35a−e, and 36a,b with an ether linkage in the central part is
presented in Scheme 3. First, the carboxylic acid 6 was reduced
to the corresponding primary alcohol 37 with borane−THF
Scheme 1. Synthesis of the Compounds with Diﬀerent Northern Partsa
aReagents and conditions: (i) 5-methyl-3-phenylisoxazole-4-carboxylic acid (6), HBTU, DIPEA, DMF, rt, 1−2 d; (ii) EtOH, mw (100 °C, 30
min); (iii) NOBF4, MeCN, 0 °C, 2 h; (iv) Zn, AcOH/MeOH (1:1), rt, overnight; (v) MeI, MeOH, mw (100 °C, 8 h); (vi) t-BuBr, TBAF, THF;
(vii) 6, (COCl)2, DMAP, py, rt, 3 d; (viii) LiOH·H2O, THF/MeOH/H2O (1+1+1), rt, 2 d; (ix) 10a−c, R2Br, K2CO3, DMF, rt, 1−4 d; 10d,
HO(CH2)2N(CH3)2, HBTU, DIPEA, DMF, rt, 3 d.
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complex. Using the Mitsunobu reaction with triphenylphos-
phine, diisopropyl azodicarboxylate (DIAD), and suitable
phenols, compound 37 was converted to the derivatives 34a,
34b, and 34c. The ketone 34a was reduced with NaBH4 in the
presence of diethylamine to the corresponding alcohol 34d,
which in turn could be alkylated with iodomethane after
deprotonation with NaH to give the ether compound 34e.
Furthermore, the ester-substituted northern part 34c was
hydrolyzed with LiOH·H2O to give the corresponding benzoic
acid 38, which was coupled with ﬁve other alcohols and two
amines to give the esters 35a−e and amides 36a,b,
respectively. Except for the synthesis of 35b, all of these
coupling reactions were performed with HBTU, employing
amines and alcohols. In contrast, compound 35b was prepared
by a nucleophilic substitution of 4-bromobutanenitrile under
basic conditions (K2CO3).
Southern Part. The synthetic routes to isoxazoles with
substituted phenyl moieties, heteroaryl residues, or ethyl
substituent in the 3 position (39a−o and 40) are described
in Scheme 4. The amide couplings of the building blocks 41a−
o and the phenylenediamines 17 and 42, respectively, were
performed with HBTU or HATU. The bromophenyl
derivative 39i was further converted to the biphenyl 39j via
tetrakis(triphenylphosphine)palladium(0)-catalyzed Suzuki re-
action. In addition, Scheme 4 presents syntheses for the
isoxazolecarboxylic acid building blocks that were not
commercially available (41f and 41l−p). The carboxylic
acids 41l−p were synthesized via 1,3-dipolar cycloaddition
reactions between nitrile oxides and ethyl 2-butynoate. The
nitrile oxide intermediates were generated from the corre-
sponding oximes 43l−p that were, in turn, prepared from the
respective aromatic aldehydes 44l−p. The 1,3-dipolar
additions were mediated by (diacetoxyiodo)benzene (DIB)35
or alternatively by Oxone.36 The resulting isoxazole esters
45l−p were hydrolyzed with either LiOH·H2O or NaOH to
produce the intermediate carboxylic acids 41l−p. Carboxylic
acid 41f was prepared from the 3-(2,6-dichlorophenyl)-5-
methylisoxazole-4-carboxylic acid 41e via nitration of the
phenyl ring by HNO3 in the presence of H2SO4.
Further, we embarked on identifying the surrogates of
isoxazole ring in the southern part. The carboxyl scaﬀolds
46a−ac were either commercially available or synthesized.
Synthesis of the triazole scaﬀolds is presented in the
Supporting Information. Carboxylic acids 46a−ac were linked
to the northern part 17 via a HBTU or HATU-mediated amide
Scheme 2. Selected Compounds with Diﬀerent Central Partsa
aReagents and conditions: (i) 5-methyl-3-phenylisoxazole-4-carbaldehyde (18), AcOH, Na2SO4 (anhydr.), THF, rt, 5 h; (ii) NaBH4, THF, MeOH,
rt, overnight; (iii) AcCl, py, rt, 4 d; (iv) 5-methyl-3-phenylisoxazole-4-sulfonyl chloride (22), py, 0 °C → rt, overnight; (v) (1) NaH, DMF, 0 °C,
1−2 h, (2) R1Br or R1I, 0 °C → rt, 1−4 d; (vi) Lawesson’s reagent, PhMe, 110 °C, 6−8 h; (vii) 24a, MeI, Li2CO3, MeCN/DMSO, 38 °C,
overnight; 24b, (1) NaH, DMF, 0 °C, 2 h, (2) Br(CH2)2F, rt, 3 d; (viii) (1) 4-(diethylamino)benzoic acid (29), (COCl)2, cat. DMF, DCM, rt, 2 h,
(2) 28, py, rt, overnight; (ix) 4-(diethylamino)benzaldehyde (32), AcOH, Na2SO4 (anhydr.), PhMe, rt, overnight; (x) NaBH4, MeOH/THF, rt, 2
d; (xi) 30a, MeI, Cs2CO3, DMF, rt, 3 d; 30b, allyl iodide, DMF, rt, 3 d; 30c, or TFAA, DMAP, py, rt, 2 d; (xii) 4-isocyanatobenzonitrile, THF, rt, 4
d.
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coupling in the presence of DIPEA (Table 1) to give the
amides 47a−ac for subsequent biological studies.
Surprisingly, our attempt to extend the isoxazole core from
the 5-position via substitution with bromine followed by an
amide coupling led to a spontaneous formation of a small
amount of imine 48 in the absence of an oxidizing reagent
(Scheme 5). 5-Methyl-3-phenylisoxazole-4-carboxylic acid 6
was brominated in the presence of N-bromosuccinimide
(NBS) and benzoylperoxide. The attempt to couple the
formed crude product 49 with N,N-diethyl-p-phenylenedi-
amine hydrochloride 50 via HBTU and DIPEA gave a small
amount (3% yield over two steps) of the imine 48. We
conﬁrmed this ﬁnding by synthesizing the imine derivative 51
without coupling reagents under microwave irradiation (120
°C, 30 min). Imine 51 was synthesized from methyl 5-methyl-
3-phenylisoxazole-4-carboxylate 52 via bromide intermediate
53. A possible explanation for the formation of an imine could
be an autoxidation of the corresponding amine obtained by a
nucleophilic substitution of bromide. Autoxidations of amines
of highly conjugated compounds have been reported
previously.37
Biology. Luciferase Reporter Assays. To screen com-
pounds for the GATA4−NKX2-5 interaction, we have
developed a luciferase reporter assay based on their property
to activate gene transcription synergistically through the
NKX2-5 binding site on DNA.28 In this assay, we transfected
mammalian COS-1 cells with protein expression vectors for
GATA4 and NKX2-5 proteins together with artiﬁcial luciferase
reporter vector containing three high aﬃnity binding sites for
NKX2-5 (NKE). As shown in Figure 3A, NKX2-5 activates the
luciferase reporter vector, and together with GATA4 the
activation is synergistic, while GATA4 alone has only a minor
eﬀect. All 257 compounds were tested in two concentrations, 3
and 10 μM. Compounds either inhibited, enhanced, or had no
eﬀect on the GATA4−NKX2-5 transcriptional synergy. To
investigate the selectivity of the active compounds, we tested
their eﬀects on NKX2-5 transcriptional activity by using the
same luciferase reporter vector as in transcriptional synergy
assay with three NKE sites (Figure 3B). Furthermore, we used
GATA luciferase reporter assay to examine if compounds have
an eﬀect on GATA4 transcriptional activity. In this assay, we
cotransfected the cells with a GATA4 protein expression vector
and a reporter vector with tandem GATA4 binding sites
(Figure 3C). Previously we have reported that compound 1
inhibited the GATA4−NKX2-5 transcriptional synergy at
micromolar concentrations (IC50 = 3 μM).
29 However, at
higher concentrations, 1 also inﬂuenced NKX2-5 (Figure 3B)
and GATA4 (Figure 3C) transcriptional activity and showed
toxicity in human induced pluripotent stem cells (iPSCs),
mouse embryonic stem cells (mESCs), and mESC-derived
progenitor cells.33
SAR Analysis. Southern Part: Scaﬀold Hopping. To
identify structural features aﬀecting inhibition of GATA4 and
NKX2-5 transcriptional synergy, we ﬁrst present an exploration
of the chemical space of the southern part of the original hit
compound 1. Table 1 presents the biological activity of
Scheme 3. Synthesis of Ethersa
aReagents and conditions: (i) BH3−THF, THF, 0 °C→ rt, 7 d; (ii) R1OH, Ph3P, DIAD, THF, 0 °C→ rt, overnight; (iii) NaBH4, Et2NH, EtOH,
35−40 °C, 3 d; (iv) (1) NaH (60 w/w%, mineral oil), DMF, 0 °C, 45 min, (2) MeI, 0 °C → rt, overnight; (v) LiOH·H2O, THF/MeOH/H2O
(1+1+1), rt, overnight; (vi) 35a and 35c−e, R2OH, HBTU, DIPEA, DMF, rt, 2−4 d; 35b, 4-bromobutanenitrile, K2CO3, DMF, rt, 4 d; (vii) R3H
(sec. amine), HBTU, DIPEA, DMF, rt, overnight.
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selected derivatives comprising diﬀerent heterocyclic scaﬀolds
in the southern part, which in turn are diﬀerently substituted
by aromatic and heteroaromatic residues as well as other
structures. Herein, we focus on the heterocyclic core of the
southern part, that is, isoxazole in 1. The compounds in Table
1 comprise other heterocycles in this region, or include an
isoxazole with an aromatic residue in its 5 position. While the
isoxazole in 1 is substituted by a phenyl group in the 3
position, many of the derivatives in Table 1 include heteroaryl
residues instead of a phenyl substituent. The presumed eﬀects
of switching the phenyl unit to a heteroaryl moiety are
discussed below together with other derivatives (Table 5).
The enhancers of the GATA4−NKX2-5 transcriptional
synergy (Table 6) seem to contain a hydrogen-bond acceptor
in the same position, indicating a role in the binding aﬃnity of
the compounds. In general, the hydrogen-bond acceptor
capacity of the isoxazole structures is strongly localized on
the nitrogen atom. In line with the reference compound 1, the
methyl-substituted furan 54 and thiophene 56 also conﬁrm this
hypothesis. We found the hydrogen-bond acceptor with one or
two atom distance to the position at which an aromatic moiety
is attached to interfere with GATA4−NKX2-5 synergy in most
structures.
A few derivatives are formally characterized by lacking the
methyl group in the 5 position of the isoxazole ring in 1. The
activities of 47d, 47e, 47n, 47p, 47t, 47z, and 54 in luciferase
assay indicate that this methyl group is not necessary for
inhibiting GATA4−NKX2-5 transcriptional synergy. Partic-
ularly noteworthy in this regard is the isothiazole 47s and the
thiophene 47u that are missing both substituents (Ph, Me).
These compounds had a clear inhibitory eﬀect on transcrip-
tional synergy. A change of the position of the aryl sustituent
further away from the central part (compounds 47b and 47y)
did not seem a promising approach. The aromatic substituent
with a one-atom spacer (compound 47q) could be further
explored, but a two-atom spacer (compound 47i) did not seem
to enhance the inhibitory eﬀect on GATA4−NKX2-5
interaction. Also, replacing the isoxazole with a bicyclic unit,
that is, 47j, 47v, 47aa, and 47ab, was not a promising
approach, although the number of these derivatives is too small
to allow drawing ﬁnal conclusions. We also note that some
derivatives with a bicyclic unit, such as 47v and 47aa, indicate
promising features for the development of enhancers of
GATA4−NKX2-5 transcriptional synergy.
Central Part: Hydrogen-Bond Accepting Heteroatoms. In
our previous study,29 we concluded that relatively rigid linkers,
such as amides or imines, are beneﬁcial moieties for inhibiting
the transcriptional synergy between GATA4 and NKX2-5, and
that a hydrogen-bond acceptor in the central part, such as the
carbonyl oxygen, linked via a one-atom spacer to the southern
part but not directly connected to the northern part may
contribute to inhibition of the transcriptional synergy between
GATA4 and NKX2-5. The luciferase assay results of the
compounds with alternative central parts (Table 2) support
our previous conclusions. Indeed, GATA4−NKX2-5 transcrip-
tional synergy was diminished with the formal removal of the
Scheme 4. Synthesis of Compounds 39a−o and 40 with Substituted Aryl and Heteroaryl Moieties Attached to the Isoxazole
Ringa
aReagents and conditions: (i) N,N-diethyl-p-phenylenediamine (17) or N,N-dimethyl-p-phenylenediamine (42), HBTU or HATU, DIPEA, DMF,
rt, 1−2 d; (ii) HNO3 (65%), H2SO4 (conc.), 0 °C, 45 min, rt, 2 h; (iii) (4-ﬂuorophenyl)boronic acid, Pd(Ph3P)4, Na2CO3, PhMe/EtOH/H2O,
EtOH, 80 °C, 5 h, 70 °C, overnight; (iv) H2NOH·HCl, py, EtOH ,rt, 1−4 h; (v) 45l−n, ethyl but-2-ynoate, DIB, TFA, MeOH or MeOH/H2O, 0
°C→ rt, 2−3 h; 45o, ethyl but-2-ynoate, PhI, Oxone, H2O, rt, 18 h; 45p, ethyl but-2-ynoate, KCl, Oxone, H2O, rt, 5 h; (vi) 45l, LiOH·H2O, THF/
MeOH/H2O, rt, overnight; 41m−o, NaOH, MeOH/H2O, 60 °C (or rt for 41o), 20−28 h.
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respective hydrogen-bond acceptor in 19, 20, 30a, 31, and 33,
and in the case of the weaker hydrogen-bond acceptors, that is,
thioamides 23 and 26, their S-alkylated derivatives 24a,b, and
tertiary amine 30b. In addition, we found that a series of
compounds that contained a carbonyl group with hydrogen-
bond accepting properties one atom further away from the
southern part, that is, the N-acylated amines 16, 30c, and 58,
showed remarkable inhibitory action on GATA4−NKX2-5
interaction. Therefore, it seems that a hydrogen-bond
accepting heteroatom in the central part is indeed beneﬁcial
for inhibiting the transcriptional synergy between GATA4 and
NKX2-5. However, regarding the distance and orientation to
the southern part, an amide linker in the central part, as in 1,
may not be an optimal moiety. Futher, we focused on the
nitrogen atom of the amide linker in the central part. An acidic
central part in compound 21 did not turn out to be a
promising approach, and, for example, the derivative with a
simple N-methyl substitution (25a) did not show inhibition of
GATA4−NKX2-5 transcriptional synergy either. However,
compounds 25b,c, having larger ﬂuoroethyl and benzyl
substituents, respectively, still had moderate inhibitory action
on GATA4−NKX2-5 interaction, indicating a potential space
for substitution in this region of the central part.
Central Part: Ether Linkers. Besides the central linkers
covered in Table 2, we investigated ether linkages (Table 3),
characterized by a hydrogen-bond acceptor connected to the
aromatic unit by a one-atom spacer. We found inhibitory
activity in the GATA4−NKX2-5 transcriptional synergy assay
Table 1. Activities of Derivatives with Structurally Diverse Southern Parts (% of Control) at 10 μM Concentrationa
aReagents and conditions: Compounds 47a−ac were synthesized from the corresponding carboxylic acids RCO2H 46a−ac (17, HBTU/HATU,
DIPEA, DMF, rt, 1−2 d). bSynthesis previously described.33 cCommercial compound (see Table S1 for details). ND, not determined.
Abbreviations: Cmpd, compound.
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Scheme 5. Autoxidation of Imines via a Secondary Amine Intermediatea
aReagents and conditions: (i) (products not isolated and characterized) NBS, (PhCO2)2, CCl4, reﬂux, 15 h (or for 53: reﬂux for 6 h and rt for 4 d);
(ii) N,N-diethyl-p-phenylenediamine hydrochloride (50), HBTU, DIPEA, DMF, rt, 2 d; (iii) N,N-diethyl-p-phenylenediamine, MeOH, mw (120
°C, 30 min).
Figure 3. Luciferase screening assays. (A) The eﬀects of compounds 1, 2, and 3 on GATA4 and NKX2-5 induced synergistic activation of the
luciferase reporter gene containing three NKX-binding sites. The assay can detect both compounds that inhibit and compounds that increase
synergistic activation. Results are the average (±SD) of several independent experiments (1, n = 87; 3, n = 4) except for compound 2 where one
experiment with three technical replicates (±SD) is presented. (B) The eﬀects of compounds 1, 2, and 3 on NKX2-5-induced reporter gene
activation. Results are average (±SD) of several independent experiments (1, n = 22; 2, n = 2; 3, n = 3). (C) The eﬀects of 1, 2, and 3 on GATA4-
induced activation of a tandem GATA-site containing luciferase reporter construct. Results are the average (±SD) of several independent
experiments (1, n = 25; 2, n = 3; 3, n = 5). N denotes NKX2-5; G, GATA4; NKE, NKX-binding site; GATA, GATA-binding site. *P < 0.05, **P <
0.01, ***P < 0.001 (randomized block ANOVA followed by a Dunnett’s post hoc test).
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for compounds, in which the northern and southern parts are
connected by an ether bridge bearing the oxygen, a hydrogen-
bond acceptor, close to the northern part. While many of the
compounds in this subset showed no signiﬁcant activity, the
retained inhibitory action on transcriptional synergy between
GATA4 and NKX2-5 in case of 34a and 34e as well as 35b and
35d demonstrated that ether bridges can be useful surrogates
of the central part. We embarked upon exploring the chemical
space in the region of the northern part’s para position. The
alcohol 34d did not show a signiﬁcant eﬀect, and the ketone
34a as well as the nitro derivative 34b only moderately
inhibited the transcriptional synergy between GATA4 and
NKX2-5. A better inhibition was observed with the benzyl
ether 34e, vaguely indicating the tolerance of bulkier
substituents. However, attempts to couple bigger residues via
ester or amide linkages gave varied results. Many of the ester
derivatives (34c, 35c, and 35e), the two amides 36a,b, and the
benzoic acid 38 showed no signiﬁcant inhibition of the
transcriptional synergy between GATA4 and NKX2-5.
Inhibition with bulky substituents was only obtained with
the esters 35a,b and 35d, which are not only bigger, but
contained also polar groups, such as carbonyl or nitrile, capable
of acting as hydrogen-bond acceptors.
Northern Part. Next we explored the chemical space
concerning the northern part and the substituent in the para
position in particular (Table 4). This set of compounds
consists of an amide linkage in the central part. The same
linkage is found in the original hit compound 1, which was the
second most potent inhibitor of the transcriptional synergy
between GATA4 and NKX2-5, only exceeded by its
homologue 4i. The meta-aryl-substituted derivatives of 1 and
4i, that is, compounds 4c, 8, and 9, were less active, indicating
limited space in the binding conformation concerning the meta
position. However, the slight synergy inhibitory potency of all
three compounds, 4c, 8, and 9, indicates that nucleophilicity or
basicity of the aniline nitrogen atom is of minor importance for
the required GATA4 and NKX2-5 protein interaction. In
addition, the moderate inhibitor 4a and the chromen-4-one
derivative 4g with potent inhibitory eﬀect on the transcrip-
tional synergy between GATA4 and NKX2-5 can formally be
regarded as meta-substituted derivatives. The greater inhibitory
activity of the latter derivative 4g as compared to 4a as well as
the missing inhibitory activity of 4d as compared to 1 indicate
once more a beneﬁt of bulky substituents beyond the northern
Table 2. Central Part Modiﬁcations and Their Activities (%
of Control) at 10 μM Concentration
aSynthesis previously described.33 ND, not determined. Abbrevia-
tions: Cmpd, compound.
Table 3. Northern Part Modiﬁcations of Ethers and Their
Activities (% of Control) at 10 μM Concentration
aND, not determined. Abbreviations: Cmpd, compound.
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part’s para position. In this respect, it is interesting to note the
missing transcriptional synergy inhibitory activity of the nitrile
derivatives 10a, 10b, and 10c. The analogous ethers 35a and
35b were potent and moderate inhibitors, respectively (Table
3). However, the striking diﬀerence in the eﬀects on GATA4−
NKX2-5 interaction of these ether linked compounds and the
corresponding amide linked analogues may not originate from
diﬀerent interactions between the small molecules and the
proteins. Although not investigated in detail, we note that
molecular stability may be the cause of diﬀerent eﬀects on
GATA4−NKX2-5 transcriptional synergy. While the ether
bridged derivatives 35a,b can be considered as phenylogous
carbonates, the amide linked 10a−c are formally phenylogous
N-aroyl carbamates. Therefore, the latter compounds may be
more prone to hydrolysis in biological media. On the
assumption of stability, however, electronic eﬀects on the
isoxazole ring may explain the diﬀerence in synergy inhibitory
activity. The sp2 carbon in 35a,b is not electron withdrawing.
Likewise, the carbonyl carbon of the linking amide in
compounds such as 1 or 4i is stabilized by the electron
delocalization in the conjugated and aromatic phenylenedi-
amine structure, so that the electron-withdrawing properties
are low. Such a stabilization does not apply to the
corresponding carbonyl carbons of 10a−c, because they are
part of phenylogous N-carbonyl carbamates. Therefore, the
carbonyl group in the central parts of 10a−c should have a
considerable electron-withdrawing eﬀect on the isoxazole ring.
Because of these possible explanations for the lack of synergy
inhibitory activity of 10a−c, the hypothesis that a bulky
substituent bearing a polar group in this molecular region
beyond the para position in the northern part is beneﬁcial for
inhibition of GATA4−NKX2-5 interaction (Table 3) remains
still noteworthy and is further supported by the inhibitory
activity of the alcohol 4b. We also note that the alkynes 15 and
4j, which can be considered nonclassical hydrogen-bond
acceptors, have slight synergy inhibiting activity. We also
found that even the cationic derivative 7 slightly retained the
GATA4−NKX2-5 transcriptional synergy inhibition.
Southern Part: Isoxazole Substituent. We explored the
chemical space in the region of the southern part further. In
our previous study,33 we reported the importance of an
aromatic substituent at the isoxazole scaﬀold of the southern
part (typically in 3-position) for the GATA4−NKX2-5
transcriptional synergy activation/inhibition and concluded
that the dihedral angle between the isoxazole and the aromatic
substituent could serve as a predictor for stem cell toxicity.33 In
this study, compounds with diﬀerently substituted phenyl
residues and derivatives with heteroaryl residues in the
southern part were synthesized to further explore the inﬂuence
of conformational as well as steric and electronic eﬀects
concerning isoxazole aryl substituents on the GATA4−NKX2-
5-induced synergistic activation of the promoter containing
three NKX2-5 binding sites. In the case of ortho-substituted
aryl residues, electronic eﬀects and steric eﬀects that likely
result in diﬀerent conformational preferences with respect to
greater dihedral angles between the two aromatic moieties
cannot be clearly distinguished from each other. However, the
luciferase assay results of this subset of compounds indicate
that ortho substitution is not beneﬁcial for the inhibition of
GATA4−NKX2-5 transcriptional synergy. The dichloro
derivatives 39e−f as well as the chloro derivative 39k and
the nitro derivative 39h were less active than the reference
compound 1. Heterocycles that contained a heteroatom in the
corresponding position (the 2 position) were at most slightly
active (39l) or not active at all (39o, 39p, 59, and 60). In the
case of ortho substituents, steric repulsions are likely to result
in unfavorable, large dihedral angles between the isoxazole and
phenyl ring. In the case of heteroatoms in the 2 position, we
assume unfavorable electrostatic interactions with the amide
linker of the central part, leading to the less optimal dihedral
angles between isoxazole and heterocycle, less optimal
orientations of the amide linker, or both. Although limited in
number, the results of these derivatives indicate that
modiﬁcation in ortho positions (the 2 position) is unlikely to
improve the inhibitory potency of GATA4−NKX2-5 tran-
scriptional synergy.
Also, meta-substituted aryl residues were less active as
synergy inhibitors as compared to 1, although 39f, 39g, and
Table 4. Selected Northern Part Modiﬁcations and Their
Activities (% of Control) at 10 μM Concentration
aND, not determined. Abbreviations: Cmpd, compound.
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39l retained some of the GATA4−NKX2-5 transcriptional
synergy inhibition. The improved activity of 39g as compared
to the inactive 40 complies with the enhanced activity of 1 as
compared to the inactive 4d (Table 4). Concerning
heteroatoms in the corresponding position (position 3 of the
aromatic substituent), the furan derivative 39n did not show
inhibition of GATA4−NKX2-5 interaction, but the thiophene
derivative 39m was a moderate synergy inhibitor. As
compound 39f was an active synergy inhibitor and 39e had
no eﬀect on GATA4−NKX2-5 transcriptional synergy, the
limited data suggest that modiﬁcations of the meta position,
that is, heteroatoms in the 3 position of a heterocycle, are
tolerated, although they do not seem to be particularly
promising for enhancing the synergy inhibitory activity.
The most promising results were obtained by alterations of
the para position, that is, replacing the carbon ring atom in the
corresponding position with a nitrogen atom. Although the
para-substituted derivatives 39a and 39j were inactive as
inhibitors of GATA4−NKX2-5 transcriptional synergy, the
para-ﬂuoro derivative 39d was as potent as 1, and also the
bromo derivative 39i and the pyridine 39c were moderately
active synergy inhibitors. The diﬀerence between the ﬂuoro
derivative 39d and the corresponding bromo derivative 39i is
commented as follows. First, as bromine has a considerably
greater atomic size than ﬂuorine, it could be hypothesized that
in the conformation of protein interaction the space around
the para position is limited. This assumption is supported by
the inactivity of 39a and 39j as synergy inhibitors. Second,
electronic eﬀects may be relevant. The greater atomic size of
bromine as compared to ﬂuorine leads also to diﬀerent
electronic properties. Aromatic halogen substituents have
inductively withdrawing (−I) and resonance donating (+M)
eﬀects. While the ﬂuoro substituent has a stronger −I eﬀect
than bromine due to its higher electronegativity, it also has a
stronger +M eﬀect. The larger sp3 orbitals of the bromo
substituent only have a poor orbital overlap with the sp2
orbitals of the much smaller carbon atoms of the phenyl ring.
Therefore, the electronic eﬀect of the 4-bromophenyl residue
in 39i on the isoxazole ring is slightly electron withdrawing,
while the eﬀect of the ﬂuorophenyl residue in 39d may be
neutral or weakly electron donating. However, as the
resonance system in 39j also consists of a ﬂuorine substituent,
the ﬁrst hypothesis, stating that bulky substitution in para
position is unfavorable, still appears as a likely one.
Although limited in number and structural variety, we
suggest a following conclusion based on this subset on
GATA4−NKX2-5 transcriptional synergy. The space around
the aryl residue attached to the isoxazole ring appears to be
limited particularly in ortho and para positions. While some
compounds with electron-withdrawing aromatic moieties
retained slight to moderate inhibition, their synergy inhibitory
activity was reduced as compared to 1, indicating that residues
at the 3 position of the isoxazole ring with electron-
withdrawing eﬀects are unfavorable. The potent synergy
inhibitory activity of 39d and the moderate inhibitory activity
of 39m leave room for the hypothesis that, in fact, small
electron-donating aromatic residues may have beneﬁcial eﬀects
for inhibiting GATA4−NKX2-5 transcriptional synergy.
Noteworthy is also the missing inhibition of GATA4−
NKX2-5 transcriptional synergy of compound 39b that
contains an alkyl residue instead of an aromatic moiety. Lack
of its synergy inhibitory activity is in agreement with our
previous conclusions,38 highlighting the importance of an
aromatic substituent at the isoxazole 3 position. However, as
the following comparisons demonstrate, analogues containing
heterocycles other than isoxazole can have high inhibitory
action on the GATA4−NKX2-5 transcriptional synergy also
without aromatic substitution (e.g., 61).
Molecular Structures Modulating GATA4 and NKX2-5
Transcriptional Synergy. In Table 6 we present collections of
the most active inhibitors and enhancers of GATA4−NKX2-5
transcriptional synergy, and in Tables 7 and 8 GATA4 and
NKX2-5 transcriptional activity, respectively. The comparison
aims at the identiﬁcation of compounds that speciﬁcally target
Table 5. Selected Compounds with Varied Isoxazole
Substituents and Their Activities (% of Control) at 10 μM
Concentration
aCommercial compound (see Table S1 for details). bSynthesis
previously described.33 cND, not determined. Abbreviations: Cmpd,
compound.
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the synergy of GATA4 and NKX2-5 but not primarily
inﬂuence on GATA4 and NKX2-5 gene transcription. In
general, we found more potent inhibitors than convincing
enhancers. Interestingly, in the GATA4−NKX2-5 luciferase
reporter assay, the most potent inhibitor was isothiazole 61. It
contains the alkyl branching in the northern part from the
inhibitory compound 4i and a small southern part with the
unsubstituted isothiazole heterocycle. The synergy inhibitory
compounds 62 and 63 had a similar alkyl branching in their
northern parts, indicating that the additional alkyl branching is
a valuable alternative to the diethylamino structure in 1.
However, the latter residue is also present in 5 of the 10 most
potent inhibitors (47c, 47s and 47u, 58, and 65) and thus
remains a suitable and promising substituent in the northern
part. While compound 61 is the most potent inhibitor in the
GATA4−NKX2-5 transcriptional synergy assay, it is likewise
the most potent inhibitor in both GATA4 and NKX2-5
transcriptional assays. As the second and fourth most potent
inhibitors in the GATA4−NKX2-5 synergy assay (Table 6),
compounds 62 and 47c are also structurally unique with 4-
methyl-1,2,3-thiadiazole substituents in the southern part.
However, compound 47c showed high toxicity in MTT assay
on cell viability (see below). Further, compounds 58 and 64,
with an N-acylated secondary amine central part, are potent
inhibitors of GATA4−NKX2-5 transcriptional synergy. The
dimethylamino residue in the northern part in 4d and 40
turned out to be inferior as compared to the diethylamino
residue in 1 and 39g, respectively. Yet compound 64 showed
moderate activity in inhibiting GATA4−NKX2-5 synergy
despite the less favorable dimethylamino residue, suggesting
the N-acylated amine in the central part to be a promising
alternative to the amide linker in 1.
Also, the ether-linked compound 35a, bearing the polar
nitrile group in the northern part side-chain, was a potent
inhibitor of GATA4−NKX2-5 synergy (Table 6), but showed
comparable inhibition in the GATA4 and NKX2-5 transcrip-
Table 6. Structure and Activity (% of Control) of the 10 Most Potent Inhibitors and Enhancers in the GATA4−NKX2-5
Synergy Assay at 10 μM Concentration
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tional assays (Tables 7 and 8). Similar conclusions apply to
compounds 47u and 63. They showed no selectivity for
GATA4−NKX2-5 synergy.
Finally, compound 65, the analogue of 1 with a reversed
substituent pattern at the isoxazole ring, was among the 10
most potent inhibitors of GATA4−NKX2-5 transcriptional
synergy. Our original hit compound 1 is not placed among the
10 most potent inhibitors in Tables 6−8, demonstrating that
the aim of this study, optimization of the hit compound 1, was
possible and successful. Various compounds with better
inhibiting potency were found, and some of them appear to
target speciﬁcally the protein−protein interaction of GATA4
and NKX2-5.
The most potent enhancer of the GATA4−NKX2-5
transcriptional synergy, compound 2, was identiﬁed in our
previous study.29 As compound 2 was also found to be a strong
enhancer in the GATA4 transcriptional assay, but not in the
NKX2-5 transcription assay, we note that the enhancing
properties of 2 largely result from an interaction with GATA4.
As the enhancing properties of most compounds are only
moderate, systematic conclusions are diﬃcult to draw.
Of note, throughout Tables 6−8, compounds devoid or
partially missing the entire northern part (47f, 66, 69, and 70)
are typically found among the enhancers of transcriptional
activity. Concerning inhibitors, compound 72 showing
inhibition potency both in transcriptional synergy and in the
GATA4 transcriptional assay (Table 7) may be regarded as a
compound lacking the northern part. Further compounds with
bicyclic arrangements in the southern part, such as 47aa and
47v, were found to have transcription enhancing properties.
Also, compounds with methyl substituents at the positions
corresponding to the isoxazole nitrogen or oxygen atom in the
Table 7. Structure and Activity (% of Control) of the 10 Most Potent Inhibitors and Enhancers in the GATA4 Luciferase
Screening Assay at 10 μM Concentration
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southern part of 1, such as 47f, 47h, and 47m, show
transcription enhancing properties. In addition, compounds
with alkyl but no aromatic substitution at the 3 and/or 5
position of the isoxazole ring, such as 39b and 47r, had
transcription enhancing properties. In particular, the derivative
39b is a very interesting compound. It is ranked the most
potent enhancer in the NKX2-5 transcriptional assay (Table 8)
and the second most active in the GATA4 assay (Table 7), but
is not included in Table 6 and has therefore a negligible eﬀect
on GATA4−NKX2-5 synergy. The pyrazole 75 has a similar
activity pattern, although its enhancing potency is weaker.
Interestingly, compound 78, a cyclic derivative of 1, in which
the orientation of the amide bond of the central part is ﬁxed,
had no eﬀect on the GATA4−NKX2-5 transcriptional synergy
and was rather a weak enhancer in the NKX2-5 transcriptional
assay (Table 8). The ﬁnding may contribute to the
understanding of the binding conformation of 1. Despite the
weak inhibiting potency of 7 (Table 4) and missing or at most
very weak enhancing properties of 10d and 4h (Table 4),
respectively, the weak enhancing capabilities of the piperidine
67, likely protonated in biological media, and of the cation 77
tentatively hint that a positive charge in the northern part may
contribute to transcriptional enhancing properties. Com-
pounds such as 47r, 47v, 67, 68, 69, and 70 seem to aﬀect
only the GATA4−NKX2-5 transcriptional synergy, but the
enhanced potency as percent of control is rather weak, making
it diﬃcult to draw convincing conclusions of this subset of
compounds.
GATA4 and NKX2-5 Transcriptional Assay. Next, we focus
on the GATA4 luciferase reporter gene assay (Table 7) and
the NKX2-5 transcriptional activity (Table 8). In particular,
the 2-nitrothiophene derivative 47u was active in all of the
assays, which indicates that its activity is not selective for the
GATA4−NKX2-5 transcriptional synergy. Also, the potent
Table 8. Structure and Activity (% of Control) of the 10 Most Potent Inhibitors and Enhancers in the NKX2-5 Luciferase
Screening Assay at 10 μM Concentration
aND, not determined.
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Figure 4. Eﬀects of the compounds 1, 2, 47c, 61, and 65 on BNP gene activation in cardiomyocytes. Neonatal cardiomyocytes were transfected
with rat BNP luciferase reporter for 24 h. The cells were exposed to compounds and 1 h later to endothelin-1 (ET-1) for 24 h. The results are
expressed as +SD (n = 3 or 9 for DMSO groups). ***P < 0.001 vs DMSO; **P < 0.01 vs DMSO; *P < 0.05 vs DMSO (one-way ANOVA followed
by Tukey’s HSD or Welch ANOVA followed by Games−Howell); ###P < 0.001 vs DMSO, no stimulus (independent samples Student’s t test).
Figure 5. Eﬀects of selected compounds on COS-1 cell viability. (A) Compound-induced necrosis was quantiﬁed with the LDH assay after a 24-h
compound exposure. The data are presented as cytotoxicity percentage (% of maximal LDH release). (B) Cell viability was analyzed with the MTT
assay after a 24-h compound exposure. (A,B) The data are means from 2−3 independent experiments with 3 replicate wells in each and are
presented as % of control (vehicle-treated cells). The compounds have been grouped on the basis of the structure of the central part: a, amide; b,
ether; c, N-acylated amine; d, amine; and e, imine. (C) The eﬀects of selected compounds on cell viability as determined by ATP content after a 24-
h compound exposure. The data are mean + SEM from three independent experiments and are presented as % of vehicle-treated cells.
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GATA4 transcriptional inhibitory activity of the phenylethyl-
substituted triazole 71, ranked in the third place in Table 7,
should be mentioned. This compound also inhibited the
NKX2-5 gene transcription (Table 8), but is not ranked among
the 10 most potent inhibitors of GATA4−NKX2-5 synergy
(Table 6). This ﬁnding hints that the chemical space around
the region of the 5-methyl group at the isoxazole core in 1 is
limited, when the GATA4−NKX2-5 interaction is targeted,
while it is less critical for interaction with either GATA4 or
NKX2-5 alone. The transcriptional enhancing properties of the
chromen-4-one bis-isoxazole derivative 73 are interesting. The
chromen-4-one derivative 4g (Table 4), derived from the hit
structure 1 by a formal exchange of the northern part, inhibits
GATA4−NKX2-5 transcriptional synergy, and likewise the bis-
isoxazole 3 (Table 1), formally derived from 1 by an exchange
of the southern part, retained inhibiting potency. The
combination of both replacements in 73 highlights the
diﬃculties in interpreting SAR. Changes in diﬀerent regions
of a hit compound are not necessarily additive. In this case, the
combination of two structural modiﬁcations with inhibiting
eﬀects turned the biological activity into the opposite and
yielded a weak enhancer in the GATA4 transcriptional assay.
The same applies to compound 74. While the formal exchange
of the northern and southern parts of 1 in 4i and 3,
respectively, yielded inhibitors, the combination of both
replacements gave the derivative 74 with enhancing eﬀects in
the GATA4 assay.
Cardiomyocyte Study. Five compounds (GATA4−NKX2-5
synergy inhibitors 1, 61, and 65; the synergy activator 2; and
the NKX2-5 activity inhibitor 47c) were selected for studies in
neonatal cardiomyocytes, which were treated with endothelin-
1 (ET-1), a well-established hypertrophic agonist that activates
the gene expression of both ANP and BNP (Figure 4). The
myocytes were transfected with construct containing −534/+4
proximal region of rat BNP promoter with GATA4 and NKX2-
5 binding sites in front of luciferase before exposure to
compounds and ET-1, which was added 1 h after the
compounds. The most potent enhancer of the GATA4 gene
transcription and synergy activation, compound 2 (Table 6),
increased BNP promoter activity, while the most potent
inhibitor of the transcriptional synergy (61, Table 6) most
strongly inhibited the BNP promoter activity in cardiomyo-
cytes. ET-1 produced about a 3-fold increase in BNP gene
activity in this assay, and compound 61 was the most potent
inhibitor of the hypertrophic response at the 30 μM
concentration. The inhibitor of NKX2-5 activity (47c)
increased BNP promoter activity in cardiomyocytes (Figure 4).
Cytotoxicity. To investigate the toxicity as a potential cause
of decreased or increased activity in luciferase reporter gene
assays, we tested a set of 40 active compounds in the COS-1
cell line used for the luciferase assays. Concentration-
dependent toxic eﬀects were investigated using the lactate
dehydrogenase (LDH) assay to detect necrosis and the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay as a measure of cell viability. None of the test compounds
induced necrosis: LDH release was always less than 8% (Figure
5A). In addition, while most of the compounds were nontoxic
in the MTT assay (Figure 5B), some of the compounds
decreased COS-1 cell viability. For the data analysis,
compounds were classiﬁed as toxic (Figures 5 and 7) if they
induced a >10% decrease in cell viability in the MTT assay at
the concentration of 10 μM. The most toxic compounds (35a,
35d, 54, 58, and 63−65) in the MTT assay all contained a
phenyl substituent in the southern part ring, while the ortho-
nitrophenyl-derivative 39g and the phenyl-substituted thio-
phene 47t were nontoxic. Higher ﬂexibility in the central parts
of the ethers (35a, 35d) and N-acylated amines (58, 64) might
contribute to their toxicity, because less rigid compounds are
more likely to have aﬃnity to various biological targets. Such
interactions can cause toxicity. To conﬁrm and validate the
results from MTT assays, we tested three nontoxic (2, 47s, and
72) and three toxic (1, 35a, and 58) compounds in a cell
viability assay measuring intracellular ATP content. The ATP
assay results are in agreement with the MTT data with
compounds 1, 35a, and 58 reducing cell viability more than
10% at 10 μM and compounds 2, 47s, and 72 exhibiting no
toxicity (Figure 5C).
Data Analysis. As shown by GATA4 and NKX2-5
luciferase reporter gene and MTT assays, modulation of
GATA and NKX2-5 transcriptional activities or cytotoxicity
Figure 6. Activity of 257 compounds in the GATA4−NKX2-5 transcriptional synergy assay at the concentration of 10 μM. Color codes: gray (0−
65% of control), orange (65−90% of control), blue (90−110% of control), and green (110−250% of control).
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may inﬂuence the activity of the compounds on the GATA4−
NKX2-5 transcriptional synergy. To facilitate data visual-
ization, compounds were divided into four groups on the basis
of their activity in the GATA4−NKX2-5 transcriptional
synergy assay (Figure 6): compounds (i) increasing synergy
(>110% of GATA4 and NKX2-5 control); (ii) having no eﬀect
on synergy (90−110% of GATA4 and NKX2-5 control); (iii)
decreasing synergy (90−65% of GATA4 and NKX2-5
control); or (iv) decreasing synergy below the combined
mean value of NKX2-5 control in all experiments (65% of
GATA4 and NKX2-5 control; see Figure 3). We hypothesized
that compounds with the luciferase activity below NKX2-5
control in GATA4−NKX2-5 transcriptional synergy assay
would inhibit either NKX2-5 or GATA4 transcriptional activity
or might be cytotoxic. Indeed, as shown in Figure 7, there is a
correlation between the NKX2-5 luciferase and GATA4−
NKX2-5 transcriptional synergy reporter gene assays, and 76%
(r2 = 0.76) of the variation in transcriptional synergy assay can
be explained with NKX2-5 luciferase reporter assay readout. A
similar correlation was observed between GATA4 luciferase
and transcriptional synergy reporter gene assays (r2 = 0.77)
(Figure 6D). When toxicities in the MTT assay (concentration
10 μM, 39 compounds) were compared to NKX2-5 and
GATA4 luciferase reporter assay readouts (Figure 7C and F),
toxicities of compounds with the cell viability >90% explained
23% (r2 = 0.23) of variability in both NKX2-5 and GATA4
reporter assays. For the most toxic compounds in the MTT
assay (the cell viability <90%), toxicity explained 69% (r2 =
0.69) of the variation in the GATA4 luciferase reporter gene
assays and 25% (r2 = 0.25) in the NKX2-5 assay. The data
were further analyzed with hierarchical clustering to identify
compounds with similar activity patterns (see Figure S1 for
more details).
Figure 7. (A) NKX2-5 luciferase reporter gene activity. (B) Relationship between the NKX2-5 luciferase reporter gene activity and the activity on
the GATA4−NKX2-5 transcriptional synergy. (C) Relationship between the cell viability in the MTT assay and the NKX2-5 luciferase reporter
gene activity. (D) GATA4 luciferase reporter gene activity. (E) Relationship between the GATA4 luciferase reporter gene activity and the activity
on the GATA4−NKX2-5 transcriptional synergy. (F) Relationship between the cell viability in the MTT assay and the NKX2-5 luciferase reporter
gene activity. Gray area: 95% conﬁdence level interval for linear model predictions. Blue line (B and E): Linear model for whole data set. Blue line
(C and F): Linear model for nontoxic compounds (cell viability >90%). Red spots: Toxic compounds (cell viability <90%). Black line: Linear
model for toxic compounds (cell viability <90%). Compounds were tested in all assays at the concentration of 10 μM.
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■ DISCUSSION AND CONCLUSION
We report the syntheses of 220 drug-like compounds together
with a comprehensive SAR analysis using three distinct
luciferase reporter assays and focusing on selected molecules
in two cell toxicity assays. Additionally, 29 commercial
compounds (see Table S1) and 8 previously published
compounds were tested and used in the SAR and data
analysis. We observed that reporter gene assays for both
GATA4 and NKX2-5 transcriptional activity relatively strongly
correlate with the GATA4−NKX2-5 transcriptional synergy
assay. The ability of the compounds to interfere with NKX2-5
transcriptional activity was plausible, as the synergistic eﬀect of
GATA4 with NKX2-5 was studied by using a promoter
containing three NKX2-5 high aﬃnity response elements.
However, the correlation between the GATA4 transcriptional
and GATA4−NKX2-5 transcriptional synergy assays is not as
obvious, because there is no GATA4 binding site in the
GATA4−NKX2-5 luciferase reporter assay. One explanation
could be allosteric modulation of GATA4, which may alter
protein conformation, such as that binding to either DNA or
NKX2-5 is attenuated. In our previous study,29 however, we
reported that the compounds did not have a statistically
signiﬁcant inﬂuence on GATA4 or NKX2-5 DNA binding
based on an electrophoretic mobility shift assay. Yet, other
direct or indirect molecular mechanisms or the presence of
GATA4 in COS-1 cells may inﬂuence GATA4 transcriptional
activity.
The SAR analysis showed that methyl substituent (located at
position 1 in the reference structure 1) is not a required feature
and that an aromatic or heteroaromatic isoxazole substituent
(located at position 3 in the reference structure 1) is often
beneﬁcial, but not essential, because also compounds such as
61 with a plain isothiazole were active, for the inhibition of
GATA4−NKX2-5 transcriptional synergy. This inhibition was
not dominated by the electronic eﬀect of the phenyl ring
substituent. It has been shown that the properties of a
heterocycle such as its dipole moment and orientation
constraints have a major impact on binding aﬃnity through
π−π interaction.38 Interestingly, thiophene in 39m was a
potent ring replacement for the phenyl ring in 1, possibly
mimicking low energy conformation, in the transcriptional
synergy assay for GATA4 and NKX2-5. The thiophene
substituent may form intra- or intermolecular noncovalent
bonds to π-systems or electron donors with its electron-
deﬁcient sulfur’s low-lying σ* orbitals of the C−S bond.39 This
view may explain why the corresponding furan derivative 39n
does not have a similar activity. Furthermore, the SAR analysis
emphasized the previously assumed29 importance of a
hydrogen-bond acceptor in the northern part of the
compounds. Interestingly, the two nitrile-substituted com-
pounds 35a and 35b were eﬀective in the GATA4 and NKX2-
5 transcriptional synergy assay. Nitrile is a known carbonyl
isostere40 further underlining the signiﬁcance of hydrogen-
bond acceptor(s), donors, or otherwise polar groups in the
northern part of the compounds. Additionally, ether linkage
and N-acylated amides in the central part were tolerated,
although free rotation of the central part might enhance the
susceptibility of compounds for unspeciﬁc binding. The steric
demand of N-alkylated amides may increase noncoplanarity of
the isoxazole and the aromatic unit in the northern part. An
ether linkage is more ﬂexible and allows noncoplanar
orientations at lower conformational energy costs. The activity
of the N-alkylated amides in the central part and the ether-
linked compounds thus hints that the optimal orientation of
isoxazole and aromatic moiety in the northern part may not be
fully coplanar. In addition, we noticed that heteroatom with a
lone pair of electrons capable of acting as a hydrogen-bond
acceptor in the positions that correspond to the isoxazole
nitrogen or oxygen in 1 was seen both in inhibitors and in
enhancers, which would indicate that it plays a role in a
binding aﬃnity of respective compounds.
It is also noteworthy to point out that a biophysical binding
assay would further advance understanding of both the
protein−ligand interaction and the molecular mechanism
leading to alteration in protein function. Because of the
importance of the physical binding data, we have applied a
number of experimental approaches, including nuclear
magnetic resonance (NMR) and microscale thermophoresis
(MST), to study the protein−ligand binding in more detail.
However, these experimental methods require large amounts
of pure protein, and so far GATA4 protein instability has
turned out to be a major challenge (unpublished observation).
Moreover, the computational models for the evaluation of
ligand binding may guide and advance the ligand optimization
and the generation of research hypotheses and, at best, directly
estimate the experimentally measured ligand aﬃnities. Because
of inaccuracies generally linked to protein models as such, and
the lack of speciﬁc experimental ligand binding data in this
particular study, we have not included docking and molecular
dynamics studies into this work. Instead of relying on
computational models alone, we are aiming to gather the
required experimental support for more complete insight.
The use of luciferase reporter assays has been associated
with several limitations. Compounds may aggregate, enzymati-
cally inhibit the reporter, have redox behavior, form
ﬂuorescence interfering complexes, interfere with the luci-
ferases, and reduce assay signal, leading to detection of false
positives.41 However, because the compounds with very similar
structures tested herein were either increasing or decreasing
signal of GATA4 and NKX2-5 transcriptional activity,
inhibition of the luciferase reporters resulting in false positives
is unlikely in the current work. Because GATA4 has an
essential role in cardiomyocyte cell survival,7 we investigated
the toxicity of a selected set of 40 compounds targeting
GATA4 and NKX2-5 transcriptional synergy in COS-1 cells
used in all luciferase reporter assays. As none of the
compounds induced signiﬁcant necrosis, and many had no
eﬀect at all on COS-1 cell viability, a rigorous threshold for
classifying compounds as toxic was set at 90% cell viability at
the concentration of 10 μM in the MTT assay. This gave us
also a method to validate the luciferase reporter assay ﬁndings.
Interestingly, we observed a 69% correlation between GATA4
transcriptional activity and MTT cell viability for compounds,
which showed over 90% toxicity, suggesting that the inhibition
of GATA4 transcriptional activity may play a role in COS-1
cell viability. The concentration−response toxicity data
identiﬁed three particularly toxic groups of compounds, that
is, ether-linked compounds, N-acylated amines, and com-
pounds with reversed substition pattern at the isoxazole ring.
Shared structural motive for these compounds is a phenyl
substituent at the isoxazole ring. This ﬁnding is in line with our
previous study, in which the southern part of such molecules
was reported to be most likely responsible of toxicity.33 In
addition, electronic eﬀects and rotational constraints of
benzene ring might contribute to toxicity of the compounds.
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The respective compounds are, however, not unsuitable for
further optimization a priori, because binding to other cellular
targets can be diminished or prevented by additional structural
modiﬁcations, which do not aﬀect or strengthen aﬃnity to
GATA4, NKX2-5, or both.
We have previously reported31 that one inhibitor of the
GATA4−NKX2-5 interaction (compound 1) had beneﬁcial
eﬀects on cardiac function and gene expression in several
experimental models of myocardial ischemia and pressure
overload in mice and rats, implicating that modulators of the
GATA4−NKX2-5 interaction may present a new class of
pharmaceuticals for myocardial remodeling and repair. We
have also tested the eﬀects of some of these compounds in
various hypertrophy assays.29,31 The compounds either
augmented or inhibited the ET-1-induced increase in ANP
and BNP mRNA levels in cardiomyocytes, consistent with the
inhibition or activation of the GATA4−NKX2-5 interaction.29
Mechanical stretch also induces hypertrophic growth of the
cardiac myocytes, as reﬂected by the increase of cardiomyocyte
cell size and activation of the ANP and BNP genes, and we
reported that compound 1 signiﬁcantly reduced the increase in
the area of the cardiomyocytes and ANP and BNP mRNA
levels in response to mechanical stretch.29,31 Moreover,
compound 1 signiﬁcantly inhibited ANP and BNP gene
expression induced by another hypertrophic agonist phenyl-
ephrine.31 In the present study, we selected several compounds
for studies in cardiomyocytes, which were treated with ET-1,
and analyzed the hypertrophic response as the activation of
BNP gene transcription. In agreement with the results using
artiﬁcial luciferase reporter vector with three high aﬃnity
binding sites for NKX2-5, the most potent enhancer of the
GATA4−NKX2-5 synergy activation (compound 2) increased
BNP promoter activity, while the most potent inhibitor
(compound 61) of the GATA4−NKX2-5 transcriptional
synergy strongly inhibited the BNP promoter activity in
cardiomyocytes. ET-1 produced about a 3-fold increase in
BNP gene activity, and compound 61 was again the most
potent inhibitor of the hypertrophic response. Overall, our
current and previous results show that the compounds acting
on GATA4−NKX2-5 transcriptional synergy can modulate the
hypertrophic response in cardiomyocytes in vitro and that the
most potent compounds inhibiting transcriptional synergy of
GATA4 and NKX2-5 possess the greatest therapeutic
potential.
Transcription factors are the central regulators of gene
expression, and their protein−protein interactions are of
pivotal importance in the regulation of biological systems.
Thus, the modulation of interactions of transcription factors
has potential to become one of the next major classes of
therapeutic targets. Cardiac transcription factors GATA4 and
NKX2-5 directly interact and synergistically activate several
genes and stretch-induced cardiomyocyte hypertrophy. Our
comprehensive SAR analysis of more than 200 structurally
related compounds accompanied by a data analysis successfully
identiﬁed inhibitors of the activity of GATA4−NKX2-5
transcriptional synergy as well as the most potent molecular
structures for the inhibition of GATA4−NKX2-5 synergy
without cellular toxicity or eﬀect on either NKX2-5 or GATA4
transcriptional activity. In further experiments, it would be
interesting to investigate the eﬀects of the compounds with
distinct actions on GATA4−NKX2-5 transcriptional synergy in
the in vitro and in vivo experimental models of cardiac
remodeling and regeneration. A more detailed assessment of
the molecular mechanism(s) of action of these modulators of
GATA4−NKX2-5 interactions is also needed to determine
whether synergy inhibitors directly bind to GATA4 or act by
some other mechanisms. In any case, the identiﬁed bioactive
compounds inhibiting synergistic GATA4 and NKX2-5 gene
activation may have potential as leads for further drug
development for the treatment of heart failure.
In conclusion, we have identiﬁed potent and selective
inhibitors of GATA4−NKX2-5 transcriptional synergy and
revealed structural features important for it. Therapeutical
potential of the most potent synergy inhibitors is exempliﬁed
by their ability to inhibit hypertrophic gene expression
response in primary rat cardiomyocytes.
■ EXPERIMENTAL SECTION
General Procedures (Chemistry). All reactions were carried out
using commercially available starting materials and reagents.
Structures and syntheses of compounds SI1−136 are shown in the
Supporting Information. Compound 1 was purchased from
Pharmatory Ltd. (Oulu, Finland). Compounds SI120−130 and 59
were purchased from Enamine (Kiev, Ukraine), compounds 57, 70,
and SI113 were from ChemBridge (San Diego, CA), compounds 66,
69, and SI114−119 were from ChemDiv (San Diego, CA), and
compounds SI133−136 were from Maybridge (Leicestershire, UK).
All chemicals, solvents, and anhydrous solvents used in the syntheses
were acquired from Sigma-Aldrich (Schnelldorf, Germany), Fluka
(Buchs, Switzerland), and Alfa Aesar (Ward Hill, MA). All moisture-
sensitive reactions were performed in ﬂame-dried glassware under an
inert argon atmosphere. The progress of chemical reactions was
monitored by thin-layer chromatography on 0.2 mm silica gel plates
(silica gel 60, F254, Merck KGaA, Darmstadt, Germany) and
visualized by UV light or ninhydrin stain (1.5% by weight in
ethanol), when applicable. Column chromatography was performed
with automated Biotage high performance ﬂash chromatography Sp4-
system (Uppsala, Sweden) using a 0.1 mm path length ﬂow cell UV-
detector/recorder module (ﬁxed wavelength 254 nm) and the
indicated mobile phase. The melting points were recorded with an
SMP40 automatic melting point apparatus (Bibby Scientiﬁc Limited,
Staﬀordshire, UK) and are uncorrected. Nuclear magnetic resonance
spectra (1H NMR and 13C NMR) were recorded on a Varian Mercury
Plus 300 (Agilent Technologies, Santa Clara, CA) or a Bruker Ascend
400-Avance III HD NMR spectrometer (Bruker Corp., Billerica, MA),
1H NMR spectra at 300 or 400 MHz, and 13C NMR spectra at 75 or
101 MHz. Chemical shifts (δ) are reported in parts per million (ppm)
relative to the NMR solvent signals (CDCl3 7.26 and 77.16 ppm,
DMSO-d6 2.50 and 39.50 ppm, for
1H and 13C NMR, respectively).
When necessary, two-dimensional NMR experiments (COSY,
NOESY, gHSQC, gHMBC) were conducted to support structure
determination. Multiplicities are indicated by s (singlet), d (doublet),
dd (doublet of dublets), t (triplet), q (quartet), and sept (septet). The
additional letter “b” indicates a broad signal, such as bs (broad
singlet). Multiplets (m) are either reported as a range of ppm values
(m) or as a centered multiplet (mc). Coupling constants J are quoted
in hertz (Hz). Exact mass and purity (>95%) of all tested compounds
were conﬁrmed by LC−MS analyses with a Waters Acquity UPLC
system (Waters, Milford, MA) equipped with an Acquity UPLC BEH
C18 column (1.7 μm, 50 mm × 2.1 mm, Waters, Ireland), an Acquity
PDA detector, and a Waters Synapt G2 HDMS mass spectrometer
(Waters, Milford, MA) via an ESI ion source in positive mode. High-
resolution mass (HRMS−ESI) data were reported for the molecular
ions [M + H]+.
General Synthetic Procedures. See the Supporting Information
for more details.
5-Methyl-N-(3-oxo-2,3-dihydro-1H-inden-5-yl)-3-phenylisoxa-
zole-4-carboxamide (4a). Synthesis was done according to general
procedure I. Deviating from general procedure I, two subsequent
chromatographic puriﬁcations were conducted, because the ﬁrst
chromatography did not give complete separation. 5-Methyl-3-
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phenylisoxazole-4-carboxylic acid (50.3 mg, 0.248 mmol), 6-amino-
indanone (36.4 mg, 0.248 mmol), HBTU (122 mg, 0.322 mmol, 1.3
equiv), DIPEA (86.4 mL, 0.496 mmol, 2 equiv), and DMF (2 mL).
Solvent for extraction: ethyl acetate and water. Recrystallization
(MeOH/H2O 10 + 1) after chromatography on silica gel gave
compound 4a (20.3 mg, 0.0611 mmol, 25%) as a beige solid. Mp
219.1−223.1 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.59 (s, 1H),
8.00 (d ≈ s, 1H), 7.77 (dd, 1H, 4J = 2.1 Hz, 3J = 8.3 Hz), 7.72−7.65
(m, 2H), 7.56 (d, 1H), 7.52−7.44 (m, 3H), 3.10−3.03 (m, 2H),
2.69−2.63 (m, 2H), 2.60 (s, 3H) ppm. 13C NMR (75 MHz, DMSO-
d6): δ 206.0, 170.1, 160.2, 150.7, 137.8, 137.0, 130.1, 128.8, 127.9,
127.7, 127.2, 126.4, 113.1, 113.0, 36.3, 25.0, 11.9 ppm. HRMS calcd
for C20H16N2O3 [M + H]
+, 333.1239; found, 333.1245.
N-[4-(Dimethylamino)phenyl]-5-methyl-3-phenylisoxazole-4-
carboxamide (4d). Synthesis was done according to general
procedure I. Deviating from general procedure I, the reaction mixture
was diluted with ethyl acetate for the workup and extracted ﬁve times
with 2 M hydrochloric acid. The combined aqueous phases were
made alkaline with a 2 M solution of sodium hydroxide in water and
extracted with ethyl acetate. The organic phase was washed twice with
a mixture of water and brine (10:1). 5-Methyl-3-phenylisoxazole-4-
carboxylic acid (0.100 g, 0.492 mmol), N,N-dimethyl-p-phenylenedi-
amine (67.0 mg, 0.492 mmol), HBTU (558 mg, 1.48 mmol, 3 equiv),
DIPEA (0.257 mL, 1.48 mmol, 3 equiv), and DMF (2.5 mL).
Recrystallization (MeOH/H2O 10 + 1) [without chromatography on
silica gel] gave compound 4d (57.0 mg, 0.177 mmol, 36%) as gray
plates. Mp 159.5−160.1 °C. 1H NMR (300 MHz, DMSO-d6): δ
10.14 (s, 1H), 7.75−7.68 (m, 2H), 7.53−7.40 (m, 3H,), 7.43 (mc,
2H), 6.71 (mc, 2H), 2.85 (s, 6H), 2.56 (s, 3H) ppm.
13C NMR (75
MHz, DMSO-d6): δ 169.4, 160.1, 159.2, 147.6, 130.1, 128.8, 128.3,
128.2, 127.7, 121.1, 113.6, 112.6, 11.9 ppm. HRMS calcd for
C19H20N3O2 [M + H]
+, 322.1556; found, 322.1553.
N-[4-[Ethyl(isopropyl)amino]phenyl]-5-methyl-3-phenylisoxa-
zole-4-carboxamide (4i). Synthesis was done according to general
procedure I. Deviating from general procedure I, the reaction mixture
was stirred at room temperature for 3 d. 5-Methyl-3-phenylisoxazole-
4-carboxylic acid 6 (2.03 g, 10.0 mmol): N-ethyl-N-isopropylpheny-
lenediamine hydrochloride (2.15 g, 10.0 mmol), HBTU (4.17 g, 11.0
mmol, 1.1 equiv), DIPEA (2.61 mL, 15.0 mmol, 1.5 equiv), and DMF
(25 mL). Solvent for extraction: ethyl acetate. Recrystallization
(MeOH/H2O 15 + 1) after chromatography on silica gel gave
compound 4i (1.59 g, 4.37 mmol, 44%) as colorless crystals. Mp
130.5−132.6 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.08 (s, 1H),
7.75−7.68 (m, 2H), 7.53−7.45 (m, 3H,), 7.41 (mc, 2H), 6.70 (mc,
2H), 3.97 (sep, 1H, 3J = 6.6 Hz), 3.19 (q, 2H, 3J = 7.0 Hz), 2.56 (s,
3H), 1.12 (d, 6H), 1.07 (t, 3H) ppm. 13C NMR (75 MHz, DMSO-
d6): δ 169.3, 160.0, 159.0, 145.1, 130.0, 128.7, 128.2, 127.6, 121.4,
113.6, 113.0, 48.0, 37.4, 19.8, 14.8, 11.9 ppm. HRMS calcd for
C22H26N3O2 [M + H]
+, 364.2025; found, 364.2025.
5-Methyl-3-phenyl-N-[4-[(trimethylsilyl)ethynyl]phenyl]-
isoxazole-4-carboxamide (4j). Synthesis was done according to
general procedure I. Deviating from general procedure I, the reaction
mixture was diluted with ethyl acetate for the workup and extracted in
the following order: once with water containing 10% brine, once with
a 2 M solution of sodium hydroxide in water, twice with 2 M
hydrochloric acid, and several times with water until the water phase
remained neutral. 5-Methyl-3-phenylisoxazole-4-carboxylic acid 6
(203 mg, 1.00 mmol): 4-[(trimethylsilyl)ethynyl]aniline (189 mg,
1.00 mmol), HBTU (569 mg, 1.50 mmol, 1.5 equiv), DIPEA (0.523
mL, 3.00 mmol, 3 equiv), and DMF (4 mL). After automated
chromatography on silica gel, which only gave partial separation, the
crude product was recrystallized once by slow evaporation of
methanol and once from MeOH/H2O (10 + 1) to yield compound
4j (64 mg, 0.17 mmol, 17%) as white needles. Mp 143.5−144.3 °C.
1H NMR (300 MHz, DMSO-d6): δ 10.62 (s, 1H), 7.70−7.60 (m,
4H), 7.52−7.41 (m, 5H), 2.58 (s, 3H), 0.22 (s, 9H) ppm. 13C NMR
(75 MHz, DMSO-d6): δ 170.2, 160.3, 160.1, 139.2, 132.4, 130.1,
128.9, 127.9, 127.8, 119.5, 117.4, 113.1, 105.2, 93.4, 12.0, 0.03 ppm.
HRMS calcd for C22H23N2O2Si [M + H]
+, 375.1529; found,
375.1525.
N-[4-(tert-Butyl)thiazol-2-yl]-5-methyl-3-phenylisoxazole-4-car-
boxamide (4k). Synthesis was done according to general procedure I.
5-Methyl-3-phenylisoxazole-4-carboxylic acid (60.0 mg, 0.295 mmol),
4-(tert-butyl)thiazol-2-amine 5k (50.8 mg, 0.325 mmol, 1.1 equiv),
HBTU (146 mg, 0.384 mmol, 1.3 equiv), DIPEA (0.103 mL, 0.591
mmol, 2 equiv), and DMF (2 mL). Solvent for extraction: diethyl
ether. Chromatography on silica gel gave compound 4k (68.9 mg,
0.0201 mmol, 68%) as a white solid. Mp 198.3−203.0 °C. 1H NMR
(300 MHz, DMSO-d6): δ 12.60 (s, 1H), 7.66−7.58 (m, 2H), 7.54−
7.47 (m, 3H), 6.83 (s, 1H), 2.59 (s, 3H), 1.26 (s, 9H). 13C NMR (75
MHz, DMSO-d6): δ 170.9, 160.4, 159.8, 156.8, 130.0, 128.8, 128.4,
128.1, 128.0, 127.8, 111.3, 105.3, 34.1, 29.7, 12.1. HRMS calcd for
C18H20N3O2S [M + H]
+, 342.1276; found, 342.1278.
4-(tert-Butyl)thiazol-2-amine (5k). 1-Bromopinacolone 14 (0.134
mL, 1.00 mmol) and thiourea (76.0 mg, 1.00 mmol) were dissolved in
ethanol (2 mL). The suspension was irradiated via microwave at 120
°C for 30 min. The resulting greenish solution was poured into a 1 M
solution of sodium hydroxide in water (25 mL) and extracted with
dichloromethane (3 × 20 mL). The combined organic phases were
washed with brine (20 mL) and dried over anhydrous Na2SO4.
Solvents were removed in vacuo to yield compound 5k (132 mg,
0.845 mmol, 85%). 1H NMR (300 MHz, CDCl3): δ 6.08 (s, 1H),
5.05 (s, 2H), 1.26 (s, 9H).
N-Ethyl-N-isopropyl-N-methyl-4-(5-methyl-3-phenylisoxazole-4-
carboxamido)benzenaminium Iodide (7). N-[4-[Ethyl(isopropyl)-
amino]phenyl]-5-methyl-3-phenylisoxazole-4-carboxamide 4i (364
mg, 1.00 mmol) was dissolved in dry methanol (3 mL). Iodomethane
(74.7 μL, 1.20 mmol) was added, and the reaction mixture was heated
at 100 °C in a microwave reactor for 8 h. The solvent was removed
with a rotary evaporator. The residue was dissolved in an equimixture
of ethyl acetate and diethyl ether, and extracted three times with a
small amount of water. The combined aqueous phases were washed
twice with an equimixture of ethyl acetate and diethyl ether. Water
was removed with a rotary evaporator, and the crude product was
recrystallized from ethanol to give compound 7 (55.0 mg, 0.109
mmol, 11%) as beige needles. Mp 132.4−134.2 °C (decomp.). 1H
NMR (300 MHz, DMSO-d6): δ 10.81 (s, 1H), 7.90−7.73 (m, 4H),
7.73−7.63 (m, 2H), 7.56−7.45 (m, 3H), 4.24 (qq ≈ sept, 1H, 3J =
6.3, 3J = 6.4 Hz), 4.11−3.98 (m, 1H), 3.95−3.80 (m, 1H), 3.44 (bs,
3H), 2.61 (s, 3H), 1.43 (d, 3H), 1.00 (d, 3H), 0.93 (dd ≈ t, 3H)
ppm. 13C NMR (75 MHz, DMSO-d6): δ 170.4, 160.4, 160.3, 139.5,
137.0, 130.2, 128.9, 127.9, 127.8, 123.3, 120.3, 112.9, 71.5, 59.2, 40.7,
16.8, 16.4, 12.1, 8.6, ppm. HRMS calcd for the cation C23H28N3O2
+
[M]+, 378.2182; found, 378.2187.
N-[4-[Ethyl(isopropyl)amino]-3-nitrophenyl]-5-methyl-3-phenyl-
isoxazole-4-carboxamide (8). N-[4-[Ethyl(isopropyl)amino]-
phenyl]-5-methyl-3-phenylisoxazole-4-carboxamide 4i (302 mg,
0.831 mmol) was dissolved in absolute acetonitrile (6 mL) under
argon and cooled to 0 °C in an ice bath. Under anhydrous conditions,
nitrosonium tetraﬂuoroborate (149 mg, 1.12 mmol) was placed under
argon and cooled to 0 °C in an ice bath. Slowly, the cold acetonitrile
solution was added to the solid nitrosonium tetraﬂuoroborate under
argon, and the reaction mixture was stirred for 2 h at 0 °C. The
solvent was removed with a rotary evaporator, and the crude product
was subjected to automated preparative chromatography. The
chromatography on silica gel with an increasing gradient of ethyl
acetate in n-hexane, starting with 0% of ethyl acetate, gave compound
8 (44.0 mg, 0.112 mmol, 13%) as an orange resin. 1H NMR (300
MHz, DMSO-d6): δ 10.73 (s, 1H), 8.11 (d, 1H,
4J = 2.5 Hz), 7.73−
7.62 (m, 3H), 7.53−7.45 (m, 4H), 3.22 (sept, 1H, 3J = 6.6 Hz), 3.02
(q, 2H, 3J = 7.0 Hz), 2.60 (s, 3H), 1.02 (d, 6H), 0.84 (t, 3H) ppm.
13C NMR (75 MHz, DMSO-d6): δ 170.3, 160.3, 160.1, 147.1, 138.7,
133.9, 130.2, 128.9, 127.9, 127.8, 126.1, 123.5, 114.8, 112.9, 54.8,
39.4, 19.5, 13.4, 12.0 ppm. HRMS calcd for C22H25N4O4 [M + H]
+,
409.1876; found, 409.1895.
N-[3-Amino-4-[ethyl(isopropyl)amino]phenyl]-5-methyl-3-phe-
nylisoxazole-4-carboxamide (9). N-[4-[Ethyl(isopropyl)amino]-3-
nitrophenyl]-5-methyl-3-phenylisoxazole-4-carboxamide 8 (36.0 mg,
0.0881 mmol) was dissolved in an equimixture of acetic acid and
methanol (0.60 mL). Zinc (18.0 mg, 0.275 mmol, 3 equiv) was added,
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and the reaction mixture was stirred overnight at room temperature.
The reaction mixture was diluted with ethyl acetate and three times
with water. The solvent was removed with a rotary evaporator, and
the product mixture was puriﬁed by automated preparative
chromatography. The chromatography on silica gel with an increasing
gradient of ethyl acetate in n-hexane, starting with 0% of ethyl acetate,
gave compound 9 (10.0 mg, 0.0264 mmol, 30%) as a white solid. Mp
111.5−113.2 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.08 (s, 1H),
7.75−7.67 (m, 2H), 7.53−7.47 (m, 3H), 7.08 (d, 1H, 4J = 2.4 Hz),
6.90 (d, 1H, 3J = 8.4 Hz), 6.74 (dd, 1H), 4.86 (s, 2H), 3.08 (sept, 1H,
3J = 6.5 Hz), 2.91 (q, 2H, 3J = 7.0 Hz), 2.55 (s, 3H), 1.01 (d, 6H),
0.81 (t, 3H) ppm. 13C NMR (75 MHz, DMSO-d6): δ 169.3, 160.1,
159.4, 146.0, 135.1, 130.9, 130.2, 128.8, 128.2, 127.6, 123.8, 113.6,
107.8, 105.8, 51.6, 40.8, 19.6, 13.1, 11.8 ppm. HRMS calcd for
C22H27N4O2 [M + H]
+, 379.2134; found, 379.2141.
Cyanomethyl 4-(5-Methyl-3-phenylisoxazole-4-carboxamido)-
benzoate (10a). Synthesis was done according to general procedure
X. 4-(5-Methyl-3-phenylisoxazole-4-carboxamido)benzoic acid 12
(43.1 mg, 0.134 mmol), bromoacetonitrile (8.90 μL, 0.134 mmol),
K2CO3 (27.8 mg, 0.201 mmol, 1.5 equiv), and DMF (1 mL).
Reaction time: 2 d. Solvent for extraction: a mixture of diethyl ether
and ethyl acetate (1:1) and water. Chromatography on silica gel gave
compound 10a (28.9 mg, 0.0800 mmol, 60%) as a white solid. Mp
189.0−190.7 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.80 (s, 1H),
7.99 (mc, 2H), 7.80 (mc, 2H), 7.72−7.64 (m, 2H), 7.53−7.45 (m,
3H), 5.20 (s, 2H), 2.60 (s, 3H) ppm. 13C NMR (75 MHz, DMSO-
d6): δ 170.4, 164.1, 160.4, 160.2, 143.7, 130.8, 130.1, 128.8, 127.8,
127.7, 122.8, 119.2, 116.0, 112.9, 49.5, 11.9 ppm. HRMS calcd for
C20H16N3O4 [M + H]
+, 362.1141; found, 362.1139.
Methyl 4-(5-Methyl-3-phenylisoxazole-4-carboxamido)benzoate
(11). 5-Methyl-3-phenylisoxazole-4-carboxylic acid (1.50 g, 7.38
mmol) was dissolved under argon in an equimixture of absolute
dichloromethane and absolute DMF (4 mL). Oxalyl chloride (0.687
mL, 8.12 mmol, 1.1 equiv) was added under argon stream within 10
min. The reaction mixture was stirred for 30 min at room temperature
and cooled to 0 °C. Absolute pyridine (5 mL) was added, and after 5
min methyl 4-aminobenzoate 13 (1.23 mg, 8.12 mmol, 1.1 equiv) and
DMAP (1.35 mg, 11.1 mmol, 1.5 equiv) were added. The reaction
mixture was stirred for 3 d at room temperature. Ethyl acetate was
added, and the organic phase was washed three times with water. The
solvent was removed with a rotary evaporator, and dichloromethane
(5 mL) and acetone (5 mL) were added. The solvents were decanted,
and the residue was dried with a rotary evaporator and recrystallized
from hot methanol. Filtration gave compound 11 (742 mg, 2.21
mmol, 30%) as white crystals. The solvent of the mother liquor was
removed with a rotary evaporator, and the residue was subjected to
automated preparative chromatography. The chromatography on
silica gel with an increasing gradient of ethyl acetate in n-hexane,
starting with 0% of ethyl acetate, gave compound 11 (121 mg, 0.360
mmol) as a white solid, increasing the yield to 843 mg, 2.51 mmol,
34%. Mp 177.1−179.4 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.74
(s, 1H), 7.96, 7.76 (each mc, each 2H), 7.72−7.65 (m, 2H), 7.53−
7.46 (m, 3H), 3.84 (s, 3H), 2.60 (s, 3H) ppm. 13C NMR (75 MHz,
DMSO-d6): δ 170.3, 165.7, 160.4, 160.2, 142.9, 130.2, 130.1, 128.8,
127.9, 127.7, 124.7, 119.1, 113.0, 51.9, 11.9 ppm. HRMS calcd for
C19H17N2O4 [M + H]
+, 377.1188; found, 377.1189.
4-(5-Methyl-3-phenylisoxazole-4-carboxamido)benzoic Acid
(12). Methyl 4-(5-methyl-3-phenylisoxazole-4-carboxamido)benzoate
11 (0.500 g, 1.49 mmol) was dissolved in an equimixture of THF,
methanol, and water (9 mL). Lithium hydroxide hydrate (81.1 mg,
1.93 mmol) was added, and the reaction mixture was stirred for 2 d at
room temperature. Diethyl ether was added, and the organic phase
was extracted twice with water and once with brine. The combined
aqueous phases were acidiﬁed with a 1 M solution of in H2O and
extracted with ethyl acetate. The organic phase was washed four times
with water until the aqueous phase remained neutral. Evaporation of
the organic phase with a rotary evaporator and drying in vacuo gave
compound 12 (464 mg, 1.44 mmol, 97%) as a white solid. Mp 217.0−
219.0 °C (decomp.). 1H NMR (300 MHz, DMSO-d6): δ 12.74 (bs,
1H), 10.70 (s, 1H), 7.93 (mc, 2H), 7.77−7.65 (m, 4H), 7.53−7.45
(m, 3H), 2.60 (s, 3H) ppm. 13C NMR (75 MHz, DMSO-d6): δ 170.7,
167.3, 160.8, 160.7, 143.0, 130.8, 130.6, 129.3, 128.4, 128.2, 126.5,
119.5, 113.6, 12.4 ppm. HRMS calcd for C18H15N2O4 [M + H]
+,
323.1032; found, 323.1032.
N-(4-Ethynylphenyl)-5-methyl-3-phenylisoxazole-4-carboxa-
mide (15). 5-Methyl-3-phenyl-N-[4-[(trimethylsilyl)ethynyl]phenyl]-
isoxazole-4-carboxamide 4j (28.9 mg, 0.0772 mmol) was dissolved
under argon in THF (1 mL). tert-Butyl bromide (44.5 μL, 0.386
mmol, 5 equiv) and a 1.0 M solution of tetra-n-butylammonium
ﬂuoride in THF (77.2 μL, 0.0772 mmol) were added, and the
reaction mixture was stirred overnight at room temperature. The
solution was diluted with ethyl acetate and washed three times with
water. The solvent was removed with a rotary evaporator, and the
crude product was puriﬁed by automated chromatography on silica
gel, using a gradient of increasing ethyl acetate starting with 100% n-
hexane to give 15 as a white solid (21.1 mg, 0.0698 mmol, 90%). Mp
148.1−150.0 °C. 1H NMR (300 MHz, DMSO-d6): δ 10.58 (s, 1H),
7.72−7.60 (m, 4H), 7.53−7.41 (m, 5H), 4.01 (s, 1H), 2.58 (s, 3H)
ppm. 13C NMR (75 MHz, DMSO-d6): δ 170.1, 160.2, 160.1, 139.0,
132.4, 130.1, 128.8, 127.9, 127.7, 119.5, 117.0, 113.1, 83.3, 80.1, 11.9
ppm. HRMS calcd for C19H15N2O2 [M + H]
+, 303.1134; found,
303.1135.
N-[4-(Diethylamino)phenyl]-N-[(5-methyl-3-phenylisoxazol-4-
yl)methyl]acetamide (16). N1,N1-Diethyl-N4-[(5-methyl-3-phenyl-
isoxazol-4-yl)methyl]benzene-1,4-diamine 20 (26.9 mg, 0.0802
mmol) was dissolved under argon in absolute pyridine (0.50 mL).
Acetyl chloride (7.40 μL, 0.104 mmol, 1.3 equiv) was added, and the
reaction mixture was shaken in a sealed tube at room temperature for
4 d. Diethyl ether was added, and the organic phase was washed three
times with water. The solvent was removed with a rotary evaporator,
and the crude product was subjected to automated preparative
chromatography. The chromatography on silica gel with an increasing
gradient of ethyl acetate in n-hexane, starting with 0% of the ethyl
acetate, gave compound 16 (27.3 mg, 0.0723 mmol, 90%) as a
colorless oil. 1H NMR (300 MHz, CDCl3): δ 7.37−7.27 (m, 5H),
6.57 (mc, 2H), 6.41 (mc, 2H), 4.81 (s, 2H), 3.30 (q, 4H,
3J = 7.1 Hz),
2.27, 1.79 (each s, each 3H), 1.14 (t, 6H, 3J = 7.1 Hz) ppm. 13C NMR
(75 MHz, CDCl3): δ 171.3, 169.5, 162.9, 147.4, 129.3, 129.3, 129.2,
128.8, 128.5, 128.3, 111.9, 110.0, 44.5, 39.9, 22.7, 12.6, 11.3 ppm.
HRMS calcd for C23H28N3O2 [M + H]
+, 378.2182; found, 378.2187.
(E)-N1,N1-Diethyl-N4-[(5-methyl-3-phenylisoxazol-4-yl)-
methylene]benzene-1,4-diamine (19). Synthesis was done according
to general procedure III. Deviating from general procedure III, THF
was used as a solvent. 5-Methyl-3-phenylisoxazole-4-carbaldehyde
(0.500 g, 2.67 mmol), N,N-diethyl-p-phenylenediamine 17 (0.444
mL, 2.67 mmol), Na2SO4 (0.400 g, 2.82 mmol), AcOH (76.5 μL, 1.34
mmol, 0.5 equiv), and THF (2.5 mL). Reaction time: 5 h at room
temperature. Chromatography on silica gel gave compound 5 (501
mg, 1.50 mmol, 56%) as an orange oil. 1H NMR (300 MHz, DMSO-
d6): δ 8.39 (s, 1H), 7.76−7.68 (m, 2H), 7.58−7.51 (m, 3H), 7.13
(mc, 2H), 6.65 (mc, 2H), 3.33 (q, 4H,
3J = 7.0 Hz), 2.78 (s, 3H), 1.08
(t, 6H, 3J = 7.0 Hz) ppm. 13C NMR (75 MHz, DMSO-d6): δ 170.9,
161.6, 146.5, 145.2, 139.1, 129.9, 128.8, 128.7, 128.1, 122.3, 112.4,
111.7, 43.8, 12.6, 12.4 ppm. HRMS calcd for C21H24N3O [M + H]
+,
334.1919; found, 334.1923.
N1,N1-Diethyl-N4-[(5-methyl-3-phenylisoxazol-4-yl)methyl]-
benzene-1,4-diamine (20). (E)-N1,N1-Diethyl-N4-[(5-methyl-3-phe-
nylisoxazol-4-yl)methylene]benzene-1,4-diamine 19 (181 mg, 0.543
mmol) was dissolved in absolute THF (3.5 mL). Sodium borohydride
(51.4 mg, 1.36 mmol, 2.5 equiv) was added, and the reaction mixture
was stirred for 2 h. An additional batch of sodium borohydride (51.4
mg, 1.36 mmol, 2.5 equiv) and absolute methanol (2 mL) were
added, and the reaction mixture was stirred overnight at room
temperature. The reaction mixture was quenched with a saturated
solution of NaHCO3 in H2O (5 mL) and after 20 min diluted with
ethyl acetate. The organic phase was washed three times with water.
The solvent was removed with a rotary evaporator, and the crude
product was subjected to automated preparative chromatography.
The chromatography on silica gel with an increasing gradient of ethyl
acetate in n-hexane, starting with 0% of ethyl acetate, gave compound
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20 (153 mg, 0.456 mmol, 84%) as a yellowish solid. Mp 75.8−77.0
°C. 1H NMR (300 MHz, DMSO-d6): δ 7.79−7.71 (m, 2H), 7.52−
7.45 (m, 3H), 6.58 (mc, 4H), 5.13 (t, 1H,
3J = 5.5 Hz), 3.95 (d, 2H, 3J
= 5.5 Hz), 3.13 (q, 4H, 3J = 7.0 Hz), 2.45 (s, 3H), 0.99 (t, 6H, 3J = 7.0
Hz) ppm. 13C NMR (75 MHz, DMSO-d6): δ 168.3, 161.9, 140.5,
140.2, 129.6, 129.1, 128.8, 127.8, 116.2, 114.0, 111.2, 44.8, 37.0, 12.3,
10.9 ppm. HRMS calcd for C21H26N3O [M + H]
+, 336.2076; found,
336.2076.
N-[4-(Diethylamino)phenyl]-5-methyl-3-phenylisoxazole-4-sul-
fonamide (21). 5-Methyl-3-phenylisoxazole-4-sulfonyl chloride (25.0
mg, 0.0970 mmol) was dissolved in anhydrous pyridine (1 mL) and
cooled to 0 °C under argon. N,N-Diethyl-p-phenylenediamine 17
(22.6 μL, 0.136 mmol) was added. After 30 min, the ice bath was
removed, and the reaction mixture was stirred overnight at room
temperature. Pyridine was removed by codistillation with toluene (3
× 10 mL) in a rotary evaporator. Automated chromatography on
silica gel, using an increasing gradient of ethyl acetate, starting with
100% n-hexane gave compound 21 (30.2 mg, 0.0783 mmol, 81%) as a
white solid. Mp 101.6−103.1 °C (decomp.). 1H NMR (300 MHz,
DMSO-d6): δ 9.59 (s, 1H), 7.53−7.44 (m, 1H), 7.44−7.37 (m, 3H),
6.75 (mc, 2H), 6.54 (mc, 2H), 3.28 (q, 4H,
3J = 7.0 Hz), 2.45 (s, 3H),
1.05 (t, 6H, 3J = 7.0 Hz) ppm. 13C NMR (75 MHz, DMSO-d6): δ
174.7, 160.7, 146.6, 130.4, 129.7, 128.5, 127.5, 126.8, 123.5, 116.2,
112.2, 44.2, 13.0, 12.7 ppm. HRMS calcd for C20H24N3O3S [M + H]
+,
386.1538; found, 386.1540.
N-[4-(Diethylamino)phenyl]-5-methyl-3-phenylisoxazole-4-car-
bothioamide (23). Synthesis was done according to general
procedure V. N-[4-(Diethylamino)phenyl]-5-methyl-3-phenylisoxa-
zole-4-carboxamide 1 (0.600 g, 1.72 mmol), Lawesson’s reagent
(417 mg, 1.03 mmol, 0.6 equiv), and toluene (12 mL). Reaction time:
6 h. Recrystallization from ethyl acetate after chromatography on
silica gel gave compound 23 (0.220 g, 0.602 mmol, 35%) as ﬁne
yellow needles. Mp 229.5−234.2 °C (decomp.). 1H NMR (300 MHz,
DMSO-d6): δ 11.71 (s, 1H), 7.72−7.65 (m, 2H), 7.60 (mc, 2H),
7.53−7.43 (m, 3H), 6.65 (mc, 2H), 3.34 (q, 4H, 3J = 7.0 Hz), 2.51 (s,
3H), 1.08 (t, 6H, 3J = 7.0 Hz) ppm. 13C NMR (75 MHz, DMSO-d6):
δ 183.9, 167.3, 158.7, 145.8, 129.9, 128.8, 128.2, 127.5, 127.4, 124.1,
110.7, 109.6, 43.7, 12.4, 11.4 ppm. HRMS calcd for C21H24N3OS [M
+ H]+, 366.1640; found, 366.1642.
N-[4-(Diethylamino)benzyl]-N,5-dimethyl-3-phenylisoxazol-4-
amine (30a). A mixture of N-[4-(diethylamino)benzyl]-5-methyl-3-
phenylisoxazol-4-amine 33 (29.9 mg, 0.0891 mmol), iodomethane
(7.80 μL, 0.125 mmol, 1.4 equiv), and cesium carbonate (40.7 mg,
0.125 mmol, 1.4 equiv) in absolute DMF (0.30 mL) was stirred for 3
d at room temperature under argon. The reaction mixture was diluted
with ethyl acetate and washed three times with water. The solvent was
removed with a rotary evaporator, and the crude product was
subjected to automated preparative chromatography. The chromatog-
raphy on silica gel with an increasing gradient of ethyl acetate in n-
hexane, starting with 0% of ethyl acetate, gave compound 30a (11.5
mg, 0.0329 mmol, 37%) as a brownish oil. 1H NMR (300 MHz,
CDCl3): δ 7.99−7.91 (m, 2H), 7.49−7.40 (m, 3H), 7.00 (mc, 2H),
6.59 (mc, 2H), 3.86 (s, 2H), 3.33 (q, 4H,
3J = 7.0 Hz), 2.6 (s, 3H),
2.31 (s, 3H), 1.15 (t, 6H, 3J = 7.1 Hz) ppm. 13C NMR (75 MHz,
CDCl3): δ 162.7, 159.8, 147.4, 130.2, 130.0, 129.4, 128.5, 128.2,
127.5, 124.5, 111.8, 60.2, 44.5, 40.9, 12.7, 12.4 ppm. HRMS calcd for
C22H28N3O [M + H]
+, 350.2232; found, 350.2236.
(E)-N-[4-(Diethylamino)benzylidene]-5-methyl-3-phenylisoxa-
zol-4-amine (31). Synthesis was done according to general procedure
III. 4-(Diethylamino)benzaldehyde (366 mg, 2.07 mmol), 5-methyl-
3-phenylisoxazol-4-amine 28 (360 mg, 2.07 mmol), Na2SO4 (587 mg,
4.13 mmol, 2 equiv), acetic acid (29.6 μL, 0.517 mmol, 0.25 equiv),
and toluene (4 mL). Chromatography on silica gel gave compound 31
(514 mg, 1.54 mmol, 74%) as yellowish crystals. Mp 119.7−120.6 °C.
1H NMR (300 MHz, DMSO-d6): δ 8.36 (s, 1H), 7.95−7.87 (m, 2H),
7.96 (mc, 2H), 7.53−7.43 (m, 3H), 6.75 (mc, 2H), 3.42 (q, 4H, 3J =
7.0 Hz), 2.47 (s, 3H), 1.13 (t, 6H) ppm. 13C NMR (75 MHz, DMSO-
d6): δ 159.2, 157.4, 146.5, 129.4, 129.3, 129.0, 128.6, 127.0, 126.1,
123.2, 111.4, 51.5, 43.6, 12.3, 10.1 ppm. HRMS calcd for C21H24N3O
[M + H]+, 334.1919; found, 334.1918.
N-[4-(Diethylamino)benzyl]-5-methyl-3-phenylisoxazol-4-amine
(33). To a solution of (E)-N-[4-(diethylamino)benzylidene]-5-
methyl-3-phenylisoxazol-4-amine 28 (0.450 g, 1.35 mmol) in an
equimixture of absolute methanol and absolute THF (8 mL) was
added sodium borohydride (76.6 mg, 2.03 mmol). The reaction
mixture was stirred overnight at room temperature. The second
portion of sodium borohydride (76.6 mg, 2.03 mmol) was added, and
the reaction mixture was stirred overnight at room temperature. The
reaction mixture was diluted with ethyl acetate, and the organic phase
was washed three times with an equimixture of water and brine. The
solvent was removed with a rotary evaporator, and the crude product
was subjected to automated preparative chromatography. The
chromatography on silica gel with an increasing gradient of ethyl
acetate in n-hexane, starting with 0% of ethyl acetate, gave compound
33 (166 mg, 0.495 mmol, 37%) as a yellowish oil. 1H NMR (300
MHz, DMSO-d6): δ 7.93−7.84 (m, 2H), 7.55−7.44 (m, 3H), 6.94
(mc, 2H), 6.55 (mc, 2H), 4.25 (t, 1H,
3J = 6.8 Hz), 3.70 (d, 2H), 3.28
(q, 4H, 3J = 7.0 Hz), 2.18 (s, 3H), 1.04 (t, 6H) ppm. 13C NMR (75
MHz, DMSO-d6): δ 159.2, 157.4, 146.5, 129.4, 129.3, 129.0, 128.6,
127.0, 126.1, 123.2, 111.4, 51.5, 43.6, 12.3, 10.1 ppm. HRMS calcd for
C21H26N3O [M + H]
+, 336.2076; found, 336.2076.
1-[4-[(5-Methyl-3-phenylisoxazol-4-yl)methoxy]phenyl]propan-
1-one (34a). (5-Methyl-3-phenylisoxazol-4-yl)methanol 37 (189 mg,
1.00 mmol), 4′-hydroxypropiophenone (0.180 g, 1.20 mmol, 1.2
equiv), and triphenylphosphine (315 mg, 1.20 mmol, 1.2 equiv) were
dissolved in anhydrous THF (4 mL) under argon and cooled to 0 °C
in an ice bath. Diisopropyl azodicarboxylate (0.236 mL, 1.20 mmol,
1.2 equiv) was added, and the reaction mixture was stirred overnight,
while the temperature was allowed to warm to rt. Diethyl ether was
added, the organic phase was washed twice with water, and the
organic solvents were removed with a rotary evaporator. The crude
product was puriﬁed by automated chromatography on silica gel,
using a gradient of increasing ethyl acetate starting with 100% n-
hexane, followed by recrystallization (MeOH/H2O 10 + 1) to give
compound 34a (254 mg, 0.790 mmol, 79%) as white crystals. Mp
117.7−122.4 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.95 (mc, 2H),
7.71−7.64 (m, 2H), 7.52−7.44 (m, 3H,), 7.11 (mc, 2H), 5.08 (s, 2H),
2.99 (q, 2H, 3J = 7.2 Hz), 2.54 (s, 3H), 1.07 (t, 3H) ppm. 13C NMR
(75 MHz, DMSO-d6): δ 198.9, 170.1, 162.1, 161.5, 130.1, 130.1,
130.0, 129.0, 128.6, 127.8, 114.7, 109.1, 59.3, 30.9, 10.9, 8.3 ppm.
HRMS calcd for C20H20NO3 [M + H]
+, 322.1443; found, 322.1443.
Propyl 4-[(5-Methyl-3-phenylisoxazol-4-yl)methoxy]benzoate
(34c). To a mixture of (5-methyl-3-phenylisoxazol-4-yl)methanol 37
(189 mg, 1.00 mmol), propyl 4-hydroxybenzoate (216 mg, 1.20
mmol, 1.2 equiv), and triphenylphosphine (315 mg, 1.20 mmol, 1.2
equiv) in anhydrous THF (4 mL) that was cooled to 0 °C in an ice
bath was added diisopropyl azodicarboxylate (0.236 mL, 1.20 mmol,
1.2 equiv). The reaction mixture was stirred overnight under argon
while the temperature was allowed to warm to rt. Ethyl acetate was
added, the organic phase was washed three times with water, and the
organic solvent was removed with a rotary evaporator. The crude
product was puriﬁed by automated chromatography on silica gel,
using a gradient of increasing ethyl acetate starting with 100% n-
hexane to give compound 34c (295 mg, 0.839 mmol, 84%) as a
colorless oil. Mp 89.1−91.4 °C. 1H NMR (300 MHz, CDCl3): δ 8.03
(mc, 2H), 7.72−7.64 (m, 2H), 7.48−7.38 (m, 3H), 6.97 (mc, 2H),
4.91 (s, 2H), 4.27 (t, 2H, 3J = 6.7 Hz), 2.52 (s, 3H), 1.79 (mc, 2H),
1.03 (t, 3H, 3J = 7.4 Hz) ppm. 13C NMR (75 MHz, CDCl3): δ 169.9,
166.4, 162.9, 161.9, 131.8, 130.0, 129.1, 129.0, 128.4, 124.0, 114.6,
109.3, 66.5, 59.8, 22.3, 11.6, 10.7 ppm. HRMS calcd for C21H22NO4
[M + H]+, 352.1549; found, 352.1548.
(rac)-1-[4-[(5-Methyl-3-phenylisoxazol-4-yl)methoxy]phenyl]-
propan-1-ol (34d). 1-[4-[(5-Methyl-3-phenylisoxazol-4-yl)methoxy]-
phenyl]propan-1-one 34a (50.0 mg, 0.156 mmol) was dissolved in
ethanol (0.50 mL). Diethylamine (0.163 mL, 1.56 mmol) and sodium
borohydride (7.10 mg, 0.187 mmol) were added, and the reaction
mixture was stirred at 35 °C overnight. The second portion of sodium
borohydride (3.5 mg, 0.094 mmol) was added, and the reaction
mixture was stirred at 40 °C for 2 d. The third portion of sodium
borohydride (7.10 mg, 0.187 mmol) was added, and the reaction
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mixture was stirred at 40 °C overnight. The reaction mixture was
diluted with ethyl acetate and washed three times with water. The
solvent was removed with a rotary evaporator, and the crude product
was puriﬁed by automated preparative chromatography. The
chromatography on silica gel with an increasing gradient of ethyl
acetate in n-hexane, starting with 0% of ethyl acetate, gave compound
34d (39.4 mg, 0.121 mmol, 78%) as an amorphous white solid. 1H
NMR (300 MHz, DMSO-d6): δ 7.74−7.67 (m, 2H), 7.52−7.45 (m,
3H), 7.23 (mc, 2H), 6.94 (mc, 2H), 4.97 (d, 1H,
3J = 4.4 Hz), 4.94 (s,
2H), 4.38 (m, 1H), 2.50 (s, 3H), 1.68−1.49 (m, 2H), 0.80 (t, 3H, 3J =
7.4 Hz) ppm. 13C NMR (75 MHz, DMSO-d6): δ 169.7, 162.0, 156.5,
139.9, 129.8, 128.9, 128.6, 127.7, 126.9, 114.5, 109.5, 73.1, 59.0, 31.9,
10.8, 10.0 ppm. HRMS calcd for C20H22NO3 [M + H]
+, 324.1600;
found, 324.1598.
(rac)-4-[[4-(1-Methoxypropyl)phenoxy]methyl]-5-methyl-3-phe-
nylisoxazole (34e). 1-[4-[(5-Methyl-3-phenylisoxazol-4-yl)methoxy]-
phenyl]propan-1-ol 34d (25.2 mg, 0.0780 mmol) was dissolved in
anhydrous DMF (0.40 mL) under argon and cooled to 0 °C in an ice
bath. A 60% dispersion of sodium hydride in mineral oil (4.7 mg, 0.12
mmol, 1.5 equiv) was added. After 45 min, iodomethane (7.3 μL, 0.12
mmol, 1.5 equiv) was added. The ice bath was removed, and the
reaction mixture was stirred overnight at room temperature. Water
and diethyl ether were added, the phases were separated, and the
organic phase was washed twice with water. The solvent was removed
with a rotary evaporator, and the crude product was puriﬁed by
automated chromatography on silica gel using a gradient of increasing
ethyl acetate, starting with 100% n-hexane to yield compound 34e
(16.9 mg, 0.050 mmol, 64%) as a colorless oil. 1H NMR (300 MHz,
CDCl3): δ 7.82−7.74 (m, 2H), 7.49−7.38 (m, 3H), 7.22 (mc, 2H),
6.90 (mc, 2H), 4.24 (d, 1H,
2J = 11.6 Hz), (dd, 1H, 3J = 6.1 Hz, 3J =
7.4 Hz), 4.09 (d, 1H), 3.83 (s, 3H), 2.33 (s, 3H), 1.94−1.78 (m, 1H),
1.74−1.59 (m, 1H), 0.88 (t, 3H, 3J = 7.4 Hz) ppm. 13C NMR (75
MHz, CDCl3): δ 169.2, 162.9, 159.4, 134.1, 129.6, 129.5, 128.8,
128.5, 128.2, 114.0, 110.9, 83.1, 59.1, 55.4, 31.2, 11.3, 10.7 ppm.
HRMS calcd for C21H24NO3 [M + H]
+, 338.1756; found, 338.1756.
2-Cyanoethyl 4-[(5-Methyl-3-phenylisoxazol-4-yl)methoxy]-
benzoate (35a). Synthesis was done according to general procedure
VII. 4-[(5-Methyl-3-phenylisoxazol-4-yl)methoxy]benzoic acid 38
(40.0 mg, 0.129 mmol), 4-hydroxypropionitrile (26.5 μL, 0.388
mmol, 3 equiv), HBTU (73.4 mg, 0.194 mmol, 1.5 equiv), DIPEA
(44.9 μL, 0.258 mmol, 2 equiv), and DMF (1.5 mL). Reaction time: 3
d. Solvent for extraction: diethyl ether and a mixture of water and 20%
brine. Chromatography on silica gel gave compound 35a (31.2 mg,
0.0861 mmol, 67%) as a white solid. Mp 109.4−111.1 °C. 1H NMR
(300 MHz, CDCl3): δ 8.04 (mc, 2H), 7.70−7.63 (m, 2H), 7.48−7.39
(m, 3H), 6.98 (mc, 2H), 4.91 (s, 2H), 4.52 (t, 2H,
3J = 6.3 Hz), 2.83
(t, 2H, 3J = 6.3 Hz), 2.53 (s, 3H) ppm. 13C NMR (75 MHz, CDCl3):
δ 169.9, 165.6, 162.9, 162.5, 132.2, 130.0, 129.1, 129.0, 128.4, 122.5,
116.9, 114.8, 109.2, 59.9, 59.1, 18.4, 11.6 ppm. HRMS calcd for
C21H19N2O4 [M + H]
+, 363.1345; found, 363.1348.
3-Cyanopropyl 4-[(5-Methyl-3-phenylisoxazol-4-yl)methoxy]-
benzoate (35b). Synthesis was done according to general procedure
X. 4-[(5-Methyl-3-phenylisoxazol-4-yl)methoxy]benzoic acid 38
(20.9 mg, 0.0676 mmol), 4-bromobutanenitrile (20.1 μL, 0.203
mmol, 3 equiv), K2CO3 (18.7 mg, 0.135 mmol, 2 equiv), and DMF (1
mL). Reaction time: 4 d. Chromatography on silica gel gave
compound 35b (26.7 mg, 0.0699 mmol, quant.) as a colorless oil.
1H NMR (300 MHz, DMSO-d6): δ 7.97 (mc, 2H), 7.71−7.64 (m,
2H), 7.53−7.44 (m, 3H), 7.12 (mc, 2H), 5.09 (s, 2H), 4.30 (t, 2H, 3J
= 6.3 Hz), 2.67 (t, 2H, 3J = 7.0 Hz), 2.54 (s, 3H), 2.07−1.97 (m, 2H)
ppm. 13C NMR (75 MHz, DMSO-d6): δ 170.1, 165.2, 162.0, 161.8,
131.4, 129.9, 129.0, 128.5, 127.8, 122.3, 120.3, 114.8, 109.1, 63.0,
59.3, 24.3, 13.6, 10.8 ppm. HRMS calcd for C22H21N2O4 [M + H]
+,
377.1501; found, 377.1505.
(5-Methyl-3-phenylisoxazol-4-yl)methanol (37). 5-Methyl-3-phe-
nylisoxazole-4-carboxylic acid 6 (2.03 g, 10.0 mmol) was dissolved in
anhydrous THF (50 mL) and cooled to 0 °C. A 1 M solution of
borane tetrahydrofuran complex in THF (15 mL, 15.0 mmol, 1.5
equiv) was added slowly via a syringe. The reaction mixture was
stirred at room temperature overnight, and the second portion of a 1
M solution of borane tetrahydrofuran complex in THF (15 mL) was
added. The reaction mixture was stirred at room temperature for 2 d,
and the third 15 mL portion of a 1 M borane tetrahydrofuran complex
solution in THF was added in two 7.5 mL portions at an interval of 7
h. The reaction mixture was stirred for 4 d and quenched with water
(10 mL). Ethyl acetate was added, and the organic phase was washed
twice with an equimixture of water and brine, once with a 2 M
solution of sodium hydroxide in H2O, and three times with water until
the water phase remained neutral. The organic solvent was removed
with a rotary evaporator, and the crude product was puriﬁed by
automated chromatography on silica gel, using a gradient of increasing
diethyl ether starting with 100% n-hexane to give compound 37 (1.00
g, 5.30 mmol, 53%) as a white solid. 1H NMR (300 MHz, DMSO-
d6): δ 7.89−7.76 (m, 2H), 7.63−7.24 (m, 3H), 5.21 (t, 3J = 5.2 Hz,
1H), 4.35 (d, 3J = 5.2 Hz, 2H), 2.46 (s, 3H) ppm. 13C NMR (75
MHz, DMSO-d6): δ 168.27, 161.88, 129.71, 129.15, 128.90, 127.99,
113.63, 51.80, 10.83 ppm.
4-[(5-Methyl-3-phenylisoxazol-4-yl)methoxy]benzoic Acid (38).
A mixture of propyl 4-[(5-methyl-3-phenylisoxazol-4-yl)methoxy]-
benzoate 34c (251 mg, 0.714 mmol) and lithium hydroxide
monohydrate (45.0 mg, 1.07 mmol, 1.5 equiv) in an equimixture of
THF, methanol, and water (3 mL). The reaction mixture was stirred
overnight at room temperature. The reaction mixture was diluted with
diethyl ether and transferred to a separatory funnel. Water was added,
and the mixture was acidiﬁed with 1 M hydrochloric acid. The phases
were separated, the organic phase was washed neutral with portions of
water, and the solvent was removed with a rotary evaporator. The
crude product was recrystallized from n-hexane/ethyl acetate (2:1) to
give compound 38 (209 mg, 0.676 mmol, 94%) as white crystals. Mp
158.3−159.2 °C. 1H NMR (300 MHz, DMSO-d6): δ 12.62 (bs, 1H),
7.90 (mc, 2H), 7.71−7.64 (m, 2H), 7.53−7.44 (m, 3H), 7.09 (mc,
2H), 5.07 (s, 2H), 2.54 (s, 3H) ppm. 13C NMR (75 MHz, DMSO-
d6): δ 170.0, 166.8, 162.0, 161.4, 131.2, 129.8, 128.9, 128.5, 127.7,
123.6, 114.7, 109.1, 59.2, 10.8 ppm. HRMS calcd for C18H16NO4 [M
+ H]+, 310.1079; found, 310.1084.
N-[4-(Diethylamino)phenyl]-3-(4-ﬂuorophenyl)-5-methylisoxa-
zole-4-carboxamide (39d). Synthesis was done according to general
procedure I. 5-(4-Fluorophenyl)-3-methylisoxazole-4-carboxylic acid
41d (52.3 mg, 0.236 mmol), N,N-diethyl-p-phenylenediamine 17
(43.2 μL, 0.0427 mmol, 1.1 equiv), HBTU (116 mg, 0.307 mmol, 1.3
equiv), DIPEA (82.3 μL, 0.061 mmol, 3 equiv), and DMF (2 mL).
Solvent for extraction: diethyl ether. Eluent for puriﬁcation: n-
heptane/ethyl acetate 9:1. Chromatography on silica gel gave
compound 39d (67.3 mg, 0.183 mmol, 77%) as a white solid. 1H
NMR (400 MHz, CDCl3): δ 7.75−7.64 (m, 2H), 7.23 (t, J = 8.6 Hz,
2H), 7.12 (mc, 2H), 6.88 (s, 1H), 6.59 (mc, 2H), 3.31 (q,
3J = 7.1 Hz,
4H), 2.75 (s, 3H), 1.13 (t, 3J = 7.1 Hz, 6H) ppm. 13C NMR (101
MHz, CDCl3): δ 174.4, 164.2 (d, J = 251.6 Hz), 159.2, 145.7, 131.3
(d, J = 8.7 Hz), 125.6, 124.3 (d, J = 3.6 Hz), 122.2, 116.6 (d, J = 21.8
Hz), 112.2, 111.8, 44.7, 13.1, 12.6 ppm. HRMS calcd for
C21H23FN3O2 [M + H]
+, 368.1774; found, 368.1776.
3-(2,6-Dichlorophenyl)-N-[4-(diethylamino)phenyl]-5-methyli-
soxazole-4-carboxamide (39e). Synthesis was done according to
general procedure I. 3-(2,6-Dichlorophenyl)-5-methylisoxazole-4-
carboxylic acid 41e (272 mg, 1.00 mmol), N,N-diethyl-p-phenyl-
enediamine 17 (0.166 mL, 1.00 mmol), HBTU (493 mg, 1.30 mmol,
1.3 equiv), DIPEA (0.348 mL, 2.00 mmol, 2 equiv), and DMF (4
mL). Solvent for extraction: diethyl ether. Recrystallization (MeOH/
H2O 20 + 1) without chromatography on silica gel gave compound
39e (347 mg, 0.830 mmol, 83%) as small white needles. Mp 145.4−
146.7 °C. 1H NMR (300 MHz, DMSO-d6): δ 9.71 (s, 1H), 7.62−7.50
(m, 3H), 7.30 (mc, 2H), 6.59 (mc, 2H), 3.28 (q, 4H,
3J = 7.0 Hz),
2.71 (s, 3H), 1.05 (t, 6H, 3J = 7.0 Hz) ppm. 13C NMR (75 MHz,
DMSO-d6): δ 169.0, 158.1, 157.8, 144.3, 134.4, 132.0, 128.2, 127.2,
127.1, 121.8, 114.6, 111.7, 43.7, 12.5, 12.3 ppm. HRMS calcd for
C21H22Cl2N3O2 [M + H]
+, 418.1089; found, 418.1089.
3-(2,6-Dichloro-3-nitrophenyl)-N-[4-(diethylamino)phenyl]-5-
methylisoxazole-4-carboxamide (39f). Synthesis was done accord-
ing to general procedure I. 3-(2,6-Dichloro-3-nitrophenyl)-5-methyl-
isoxazole-4-carboxylic acid 41f (75.0 mg, 0.237 mmol), N,N-diethyl-p-
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phenylenediamine 17 (39.3 μL, 0.237 mmol), HBTU (117 mg, 0.308
mmol, 1.3 equiv), DIPEA (82.6 μL, 0.474 mmol, 2 equiv), and DMF
(1.5 mL). Solvent for extraction: diethyl ether. Recrystallization
(MeOH/H2O 20 + 1) after chromatography on silica gel gave
compound 39f (75.0 mg, 0.162 mmol, 68%) as orange needles. Mp
89.7−95.5 °C (decomp.). 1H NMR (300 MHz, DMSO-d6): δ 9.87 (s,
1H), 8.27 (d, 1H, 3J = 8.8 Hz), 7.92 (d, 1H), 7.30 (mc, 2H), 6.59 (mc,
2H), 3.28 (q, 4H, 3J = 7.0 Hz), 2.75 (s, 3H), 1.04 (t, 6H, 3J = 7.0 Hz)
ppm. 13C NMR (75 MHz, DMSO-d6): δ 169.9, 157.6, 157.5, 147.23,
144.5, 138.3, 129.9, 129.5, 127.5, 126.8, 126.7, 122.1, 114.5, 111.7,
43.8, 12.8, 12.3 ppm. HRMS calcd for C21H21Cl2N4O4 [M + H]
+,
463.0940; found, 463.0938.
3-(2,6-Dichloro-3-nitrophenyl)-5-methylisoxazole-4-carboxylic
Acid (41f). 3-(2,6-Dichlorophenyl)-5-methylisoxazole-4-carboxylic
acid 41e (136 mg, 0.500 mmol) was dissolved in conc. sulfuric acid
(1 mL) and cooled to 0 °C in an ice bath. A 65% solution of nitric
acid in H2O (0.50 mL) was added slowly, and the reaction mixture
was stirred at 0 °C for 45 min and 2 h at room temperature. The
reaction mixture was cooled in an ice bath, and crushed ice (50 mL)
was added slowly in small portions. Filtration and recrystallization
(EtOH/H2O 10 + 1) gave the crude compound 41f (135 mg, 0.426
mmol, 85%) as white crystals. 1H NMR (300 MHz, DMSO-d6): δ
13.26 (s, 1H), 8.28 (d, 1H, 3J = 8.8 Hz), 7.94 (d, 1H), 2.78 (s, 3H)
ppm. 13C NMR (75 MHz, DMSO-d6): δ 176.2, 161.5, 157.6, 147.1,
138.1, 130.2, 129.3, 127.5, 126.5, 109.5, 12.8 ppm. HRMS calcd for
C11H6Cl2N2O5 [M + H]
+, 316.9732; found, 316.9733.
N-[4-(Diethylamino)phenyl]-3-methyl-5-(4-methyl-1,2,3-thiadia-
zol-5-yl)isoxazole-4-carboxamide (47c). Synthesis was done accord-
ing to general procedure I. 3-Methyl-5-(4-methyl-1,2,3-thiadiazol-5-
yl)isoxazole-4-carboxylic acid 46c (50.0 mg, 0.222 mmol), N,N-
diethyl-p-phenylenediamine hydrochloride, 50 (78.6 mg, 0.392 mmol,
1.2 equiv), HBTU (126 mg, 0.333 mmol, 1.5 equiv), DIPEA (77.3
μL, 0.444 mmol, 2 equiv), and DMF (1.5 mL). Solvent for extraction:
ethyl acetate. Recrystallization (MeOH/H2O 10 + 1) after
chromatography on silica gel gave compound 47c (49.0 mg, 0.132
mmol, 59%) as dark yellow crystals. Mp 103.1−106.9 °C. 1H NMR
(300 MHz, DMSO-d6): δ 10.11 (s, 1H), 7.40 (mc, 2H), 6.66 (mc,
2H), 3.31 (q, 4H, J = 7.0 Hz), 2.89 (s, 3H), 2.47 (s, 3H), 1.07 (t, 6H,
J = 7.0 Hz) ppm. 13C NMR (75 MHz, DMSO-d6): δ 158.9, 158.4,
157.9, 157.8, 144.8, 134.2, 126.3, 121.9, 117.6, 111.7, 43.7, 13.9, 12.3,
10.3 ppm. HRMS calcd for C18H22N5O2S [M + H]
+, 372.1494; found,
372.1493.
N-[4-(Diethylamino)phenyl]-3-(1H-tetrazol-1-yl)-1H-pyrazole-4-
carboxamide (47g). Synthesis was done according to general
procedure I. 3-(1H-Tetrazol-1-yl)-1H-pyrazole-4-carboxylic acid 46g
(21.6 mg, 0.120 mmol), N,N-diethyl-p-phenylenediamine 17 (27.9
μL, 0.168 mmol, 1.4 equiv), HBTU (59.2 mg, 0.156 mmol, 1.3
equiv), DIPEA (20.9 μL, 0.240 mmol, 2 equiv), and DMF (1 mL).
Solvent for extraction: ethyl acetate and water/brine (2:1).
Chromatography on silica gel gave compound 47g (21.7 mg,
0.0665 mmol, 55%) as a grayish solid. Mp 218.5−225.6 °C
(decomp.). 1H NMR (300 MHz, DMSO-d6): δ 13.82 (br s, 1H),
9.84 (s, 1H), 9.76 (s, 1H), 8.63 (s, 1H), 7.35 (mc, 2H), 6.62 (mc,
2H), 3.29 (q, 4H, 3J = 7.0 Hz), 1.06 (t, 6H, 3J = 7.0 Hz) ppm. 13C
NMR (75 MHz, DMSO-d6): δ 158.1, 145.2, 144.4, 141.1, 131.7,
126.9, 122.0, 111.7, 111.2, 43.7, 12.3 ppm. HRMS calcd for
C15H18N8O [M + H]
+, 327.1682; found, 327.1679.
PAINS. All compounds reported in this Article were electronically
matched against known pan assay interference (PAINS42) sub-
structures by using the zinc database43 web application (https://
zinc15.docking.org/patterns/home/). Compounds 30a−d, 33, 64,
SI43, SI84, SI92, SI94, and SI109 contained anil_di_alk_D
structural alert. In addition, compounds SI20, SI95, SI96, and SI97
contained azo_A structural alert. Aggregation of the selected
compounds was researched in our previous study,29 and none of
the tested compounds showed aggregating behavior in assay
concentrations.
Experimental Procedures (Biology). Plasmids. The plasmids
expressing mouse GATA4 protein, pMT2-GATA4, and empty pMT2
were gifts from D. B. Wilson (Department of Pediatrics, St. Louis
Children’s Hospital, St. Louis, MO).44 The plasmids expressing
mouse NKX2-5 protein, pMT2-NKX2-5, have been described
earlier.28 The luciferase reporter plasmid used in GATA4−NKX2-5
transcriptional synergy assay and NKX transcriptional assay, pGL3-
3xHA, contains three high aﬃnity binding sites for NKX2-5.28 The
luciferase reporter plasmid used in GATA transcriptional assay, NP-
112, contains tandem GATA-sites and minimal promoter of rat brain
natriuretic peptide (BNP) gene.45 The pGL3-BNP luciferase reporter
containing −534/+4 bp rat BNP proximal promoter described
previously was used in hypertrophy assay.46
Luciferase Assays. The primary screening assay of compounds’
eﬀect on GATA4−NKX2-5 transcriptional synergy and COS-1 cell
culturing has been described earlier.33 COS-1 cells do not express
endogenous NKX2-5 protein and a very low amount of GATA4
protein28 (Kinnunen et al., unpublished observation). Brieﬂy, COS-1
cells were seeded at 14 000 cells/well in Isoplate-96 microplates
(PerkinElmer, Turku, Finland) and grown overnight. The cells were
transfected with the luciferase reporter plasmid pGL3-3xHA 100 ng/
well and equal amounts of expression plasmids pMT2-GATA4 and
pMT2-NKX2-5 total 50 ng/well. To verify the synergistic eﬀect, the
cells were transfected with pMT2-GATA4 or pMT2-NKX2-5 25 ng/
well, and the total DNA concentration was adjusted to 50 ng/well
with empty pMT2 plasmid. In NKX2-5 and GATA4 luciferase
reporter assays, the cells were transfected with reporter plasmid
pGL3-3xHA or NP-112 (100 ng/well) and expression plasmid pMT2-
NKX2-5 or pMT2-GATA4 (25 ng/well). The ratio of DNA/
transfection reagent (Fugene 6, Promega) was 1:3 in all assays. The
transfections were performed in serum and antibiotics free media for 6
h. The cells were treated with compounds or vehicle (0.1% DMSO)
for 24 h, and the luminescence was measured using neolite Reporter
Gene Assay System (PerkinElmer, Turku, Finland) and Victor2 plate
reader (PerkinElmer, Turku, Finland).
Cardiomyocyte Studies. The neonatal rat ventricular myocytes
were isolated from 2- to 3-day-old Wistar rats, as described earlier.29,32
Rat pups were acquired from the experimental animal facility of the
University of Helsinki with an internal use license (KEK17-012).
Animals were housed in standard conditions, and their handling and
all procedures were carried out in accordance with University of
Helsinki institutional guidelines, which conform to the National
Research Council (U.S.) Guide for the Care and Use of Laboratory
Animals.47 The cells were seeded at 50 000 cells/well in Isoplate-96
microplates (PerkinElmer, Turku, Finland) and cultured for 18−20 h
with Dulbecco’s modiﬁed Eagle medium (DMEM)/F12 culture
medium containing 2.5 mM L-glutamine, supplemented with 100 IU/
mL penicillin−streptomycin and 10% fetal bovine serum (all from
Gibco, Thermo Scientiﬁc). Transfections were carried out for 24 h in
serum free media (CSFM; DMEM/F12, 2.5 mg/mL bovine serum
albumin, 1 μM insulin, 2.5 mM L-glutamine, 32 nM selenium, 2.8 mM
sodium pyruvate, 5.64 μg/mL transferrin, 1 nM T3, and 100 IU/mL
PS) by using 100 ng of pGL3-BNP luciferase plasmid per well in a 1:3
ratio of DNA/transfection reagent (Fugene 6, Promega). The
compounds or the vehicle (0.1% DMSO) were added to cells in
CSFM media and endothelin-1 (E7764, Sigma-Aldrich) 1 h later.
After 24 h, the luminescence was measured as above.
Toxicity Experiments. For toxicity screening, COS-1 cells were
cultured in DMEM (Sigma-Aldrich, Steinheim, Germany) supple-
mented with 10% fetal bovine serum, 100 U/mL penicillin, and 100
μg/mL streptomycin (all from Gibco, Thermo Scientiﬁc) at 37 °C
with 5% CO2. The cells were plated on 96-well plates at 10 000 cells/
well and exposed to test compounds at a concentration range of 1−30
μM on the following day. After a 24-h compound treatment, lactate
dehydrogenase (LDH) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assays were carried out as described
previously.48 Brieﬂy, LDH activity was determined from 50 μL
samples of cell culture medium, to which 50 μL of substrate solution
[1.3 mM β-nicotinamide-adenine dinucleotide, 660 μM iodonitrote-
trazolium, 54 mM L(+)-lactic acid, and 280 μM phenazine
methosulfate in 0.2 M Tris-HCl, pH 8.2, all from Sigma-Aldrich]
was added, and the plate was incubated for 30 min at room
temperature. The reaction was stopped with acetic acid (ﬁnal
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concentration 333 mM), and absorbance was measured at 490 nm.
The absorbance values of the samples were normalized to maximal
LDH release and spontaneous LDH release determined on the same
plate. Mitochondrial metabolic activity was quantiﬁed by incubating
the cells with 0.5 mg/mL MTT (from Sigma-Aldrich) for 2 h at 37 °C
with 5% CO2, whereafter culture medium was removed and formazan
crystals were dissolved in DMSO. The absorbance was measured at
550 nm, and absorbance at 650 nm was subtracted as background.
A selected set of compounds were tested also in the ATP assay by
using CellTiter-Glo Luminescent Cell Viability assay (Promega).
Subculturing and treatment of COS-1 cells were otherwise performed
similar to that in the MTT test, but the ﬁnal volume of treatment was
200 μL per well. Doxorubicin was used as a positive control in the
assay. After treatment, the plates were equilibrated at room
temperature for 30 min, after which the media was removed and
cells were washed with 100 μL of PBS. Next, 50 μL of fresh media and
50 μL of mixed CellTiter Glo Reagent were added to the plate. The
contents of the plates were mixed for 2 min, and incubated at room
temperature for 15 min. The luminescence was measured with
VarioskanTM LUX Multimode Plate Reader (Thermo Fisher
Scientiﬁc, Waltham, MA) using SkanItTM Software 5.0.
Data Analysis and Statistics. Raw luciferase data were analyzed in
Excel, and clear outliers were removed from triplicates by using the
Grubb’s test. Data analysis was performed using R.49 The luciferase
data were ﬁrst normalized on the basis of the combined mean value of
controls. For data visualization and creation of ﬁgures, the following R
packages were used: ggplot2, cowplot, RColorBrewer, and pheatmap.
The heatmaps of the toxicity data were produced with GraphPad
Prism 7.00 (GraphPad Software, La Jolla, CA). Statistical signiﬁcance
of luciferase reporter assay data was evaluated by randomized block
analysis of variance followed by Dunnett’s post hoc test. A probability
value of P < 0.05 was considered statistically signiﬁcant. Randomized
block analysis of variance was used to block batch variation from the
analysis. Statistical analysis for luciferase reporter assay data was
conducted before normalization to control.
Results from cardiomyocyte experiments are expressed as mean +
SD from at least three independent experiments. Data were analyzed
using IBM SPSS Statistics 24 software. Levene’s test was used to test
homogeneity of variances. If the data met the assumptions of the test,
one-way ANOVA followed by Tukey HSD post hoc test were carried
out; otherwise Welch ANOVA followed by Games−Howell post hoc
test were performed. Signiﬁcance between ET-1 and DMSO samples
was analyzed with independent samples Student’s t test. Diﬀerences at
the level of P < 0.05 were considered statistically signiﬁcant.
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(29) Val̈imak̈i, M. J.; Tölli, M. A.; Kinnunen, S. M.; Aro, J.; Serpi, R.;
Pohjolainen, L.; Talman, V.; Poso, A.; Ruskoaho, H. J. Discovery of
Small Molecules Targeting the Synergy of Cardiac Transcription
Factors GATA4 and NKX2−5. J. Med. Chem. 2017, 60 (18), 7781−
7798.
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